 
 
Clinical Development  
LCZ696 
Clinical Trial Protocol CLCZ696BUS01 / [STUDY_ID_REMOVED]
A 
multicenter, r andomized, do uble-blind, d ouble du mmy, 
parallel group, active- controlled [ADDRESS_167660] of sacubitril/valsartan (LC Z696) versus enalapril 
on changes in NT-proBNP and safety and tolerability of in- 
hospi[INVESTIGATOR_307] i nitiation of LCZ696 c ompared to enalapril i n 
HFrE F patients who have be en stabilized following 
hospi[INVESTIGATOR_146440] e decompensated heart failure 
(ADHF). 
Author (s): 
Document  ty pe: Amended Protocol  Version  
EUDRACT  number  Not applicable  
Version  number  v02 Clean  
Development  phase  IIIb/IV 
Document  status: Final 
Release  date:  05-Oct- 2017
Property of [COMPANY_001] 
Confidential  
May not be used, divulged, published or otherwise disclosed 
without the consent of [COMPANY_001]  
Template version 02- Dec- 2013  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167661] of abbreviations  ............................................................................................................ 6 
Glossary  of terms  ................................................................................................................. 9 
Protocol summary  .............................................................................................................. 11 
1 Introduction ....................................................................................................................... 18 
1.1 Background  ............................................................................................................ 18 
1.2 Rationale for  protocol amendment  ........................................................................ 21 
1.3 Changes  to protocol  ............................................................................................... 22 
1.4 Purpose  .................................................................................................................. 22 
2 Study objectives  ................................................................................................................. 22 
2.1 Primary  objective(s)  ............................................................................................... [ADDRESS_167662] igational plan............................................................................................................ 24 
3.1 Study design  ........................................................................................................... 24 
3.2 Rationale of study design  ....................................................................................... 25 
  25 
3.4 Rationale for choice of comparator  ....................................................................... 26 
3.5 Purpose and timing of interim analyses/design  adaptations  .................................. 26 
3.6 Ri
sks and benefits  .................................................................................................. 26 
4 Population  .......................................................................................................................... 27 
4.1 Inclusion c riteria  .................................................................................................... 28 
4.2 Exclusion criteria  ................................................................................................... 28 
5 Treatment  ........................................................................................................................... 30 
5.1 Protocol requested  treatment  ................................................................................. 30 
5.1.1 Investigational and control treatment  .................................................... 30 
5.1.2 Additional study treatment .................................................................... 31 
5.2 Treatment  arms  ...................................................................................................... 31 
5.3 Treatment assignment, randomization  ................................................................... 31 
5.4 Treatment  blinding ................................................................................................. 32 
5.5 Treat ing the patient  ................................................................................................ 33 
5.5.1 Patient  numbering ................................................................................. 33 
5.5.2 Dispensing the investigational and comparator treatment .................... 33 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167663]-study treatment .......................................... 41 
5.5.13  Early  study termination  ......................................................................... 41 
6 Visit schedule  and assessments  ......................................................................................... 41 
6.1 Information to be coll ected on  screening  failures  .................................................. 43 
6.2 Patient demographics/other baseline characteristics  .............................................. [ADDRESS_167664]/hip  circumference  ......................................... 47 
6.5.4 Angioedema  .......................................................................................... 47 
6.5.5 Laboratory  evaluations  .......................................................................... 47 
6.5.6 Pregnancy and assessments  of fertility  .................................................. 48 
6.5.7 Appropriateness of safety  measurements  .............................................. 48 
  48 
 
 48 
  49 
7 Safety  monitoring  .............................................................................................................. 49 
7.1 Adverse events  ....................................................................................................... 49 
7.2 Serious adverse events  ........................................................................................... 50 
7.2.1 Definition  of SAE .................................................................................. 50 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 4 
Protocol No. CLCZ696BUS01   
 7.2.2 SAE reporting  ........................................................................................ 51 
7.3 Reporting of study treatment errors including misuse/abuse  ................................. 52 
7.4 Pregnancy  reporting ............................................................................................... 52 
7.5 Reporting angioedema -like events  ......................................................................... 53 
8 Data review and  database  management  ............................................................................. 53 
8.1 Site monitoring  ...................................................................................................... 53 
8.2 Data collection  ....................................................................................................... 54 
8.3 Database management and  quality control  ............................................................ 54 
8.4 Data Monitoring Committee  .................................................................................. 55 
8.5 Adjudication Committee  ........................................................................................ 55 
9 Data analysis  ...................................................................................................................... 56 
9.1 Analysis  sets .......................................................................................................... 56 
9.2 Patient demographics and other baseline characteristics  ....................................... 56 
9.3 Treatments  ............................................................................................................. 57 
9.4 Analysi s of the  primary  variable(s)  ....................................................................... 57 
9.4.1 Variables  ............................................................................................... 57 
9.4.2 Statistical model, hypothesis, and method  of analysis  .......................... 57 
9.4.3 Handling of missing values/censoring/discontinuations  ....................... 58 
9.4.4 Supportive analyses  ............................................................................... 58 
9.5 Analysis of secondary  variables  .................................................. 58 
9.5.1 Secondary  variables  ............................................................................... 58 
  58 
9.5.3 O
ther safety  variables  ............................................................................ 61 
  61 
9.5.5 Pharmacokinetics  .................................................................................. 61 
9.5.6 Pharmacogenetics  and pharmacogenomics  ........................................... 61 
9.5.7 Biom arkers  ............................................................................................ 62 
9.5.8 PK/PD  ................................................................................................... 62 
9.6 Interim analyses  ..................................................................................................... 62 
9.7 Sample  size calculation  .......................................................................................... 62 
10 Ethical  considerations  ........................................................................................................ 63 
10.1 Regulator y and  ethical compliance  ........................................................................ 63 
10.2 Informed  consent procedures  ................................................................................. 63 
10.3 Responsibilities of the investigator  and IRB/IEC  .................................................. 63 
10.4 Publication of study protocol and results  ............................................................... 64 
11 Protocol adherence  ............................................................................................................ 64 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 5 
Protocol No. CLCZ696BUS01   
 11.1 Protocol Amendments  ........................................................................................... 64 
12 References  ......................................................................................................................... 64 
13 Appendix 1: Clinically notable laboratory values  ............................................................. 67 
14 Appendix 2: Treatment  guidelines for hyperkalemia (serum  potassium greater  than 
or equal to 5.5 mEq/L)  ....................................................................................................... 68 
15 Appendix 3: Guidelines for the management of blood pressure  ....................................... 69 
16 Appendix 4: Guidelines for the management of renal  dysfunction  ................................... [ADDRESS_167665] of tables 
Table 1 -1 Adverse reactions occurring at an incidence of >5% of patients  in 
the double-blind period of PARADIGM- HF were  as follows:  ............. 20 
Table 5 -1 Investigational and comparator  treatment  ............................................. 30 
Table 5 -2 Treatment  Dose  Levels  ......................................................................... 30 
Table 5 -3 Dose titration schedule based  on SBP ................................................... 35 
Table 6 -1 Assessment  schedule  ............................................................................. 42 
Table 7 -1 Guidance for capturing the study treatment errors including 
misuse/abuse  ......................................................................................... 52 
Table 9 -1 Sample size and power for various rate of reduction in 
sacubitril/valsartan group given  alpha =0.05:  ...................................... [ADDRESS_167666] of figures 
Figure 3 -1 Study Design  ......................................................................................... 25 
Figure 3 -2 36 hour washout design  ......................................................................... 27 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167667]  aspartate  aminotransferase 
AUC  area under the curve 
b.i.d. twice a day  
BMI  Body mass  index 
BNP  B- type n atriuretic  peptide 
BP blood pressure  
Bpm  beats per  minute  
CHF  chronic heart failure  
CFR  US Code of Federal  Regulations 
CDS  Core Data Sheet (for  marketed  drugs) 
COPD Chronic obstructive pulmonary disease 
CPO  Country Pharma Organization  
CRA  clinical research  associate (site monitor) 
CRF  Case Report/Record Form (paper  or electronic) 
CRO  Contract Research Organization  
CRTD  Cardiac resynchronization  therapy  device 
CSR  Clinical Study  Report 
CTL  Clinical Trial Leader  
CV cardiovascular  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 7 
Protocol No. CLCZ696BUS01   
  
DBP  diastolic blood pressure 
DMC  Data Monitoring Committee  
DS&E  Drug Safety &  Epi[INVESTIGATOR_146441]-Troponin high sensitivity  troponin 
HTN  hypertension 
IA interim analysis  
ICH International Conference on Harmonization of Technical   Requirements  for 
Registration of Pharmaceuticals for Human  Use 
IEC Independent Ethics Committee  
IN investigator  notification  
i.v. intravenous 
IRB Institutional Review  Board  
IWRS  Interactive Web Response System  
  
LFT Liver function test (raised serum transaminases and/or bilirubin levels) 
LVAD  Left ventricular assist device 
LVEF  Left ventricular  ejection  fraction  
LVESV  left ventricular end  systolic  volume 
LVH  left ventricular  hypertrophy  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167668]  upper limit of  normal 
USPI  [INVESTIGATOR_146442]/package insert  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167669] ug Any drug (an active drug or an inactive drug, such as a placebo) 
which is used as a comparator to the drug being tested in the trial  
Enrollment  Point/time of patient entry into the study at which informed 
consent must be obtained (i.e. prior to starting any of the 
procedures described in the protocol)  
Investigational drug  The drug whose properties are being tested in the study; this definition is consistent with US CFR 21 Section 312.3 and is synonymous with “investigational new drug” or “investigational 
medicinal product.”  
Investigational treatment  All investigational drug(s) whose properties are being tested in the 
study as well as their associated treatment controls.  
This includes any placebos, any active controls, as well as 
approved drugs used out side of their indication/approved dosage 
or tested in a fixed combination.  
Investigational treatment generally does not include  protocol - 
specified concomitant background therapi[INVESTIGATOR_146443]  A unique identifier on the label of each investigational/study drug 
package in studies that dispense medication using an IRT system  
Protocol  A written account of all the procedures to be followed in a trial, which describes all the administrative, documentation, analytical 
and clinical processes used in the trial.  
Part A single component of a study which contains different objectives 
or populations within that single study. Common parts within a 
study are: a single dose part and a multiple dose part, or a part in 
patients with established disease and in those with newly - 
diagnosed disease.  
Period  A subdivision of a cross -over study  
Premature subject/patient withdrawal
 Point/time when the patient exits from the study prior to the 
planned completion of all study treatment administration and/or 
assessments; at this time all study treatment administration is discontinued and no further assessments are planned, unless the 
patient will be followed for progression and/or survival  
Randomization number  A unique identifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment  
Study drug/ treatment  Any single drug or combination of drugs administered to the patient as part of the required study procedures; includes 
investigational drug (s), active drug run -ins or background therapy  
Study/investigational treatment discontinuation
 Point/time when patient permanently stops taking study/investigational treatment for any reason; may or may not also be the point/time of premature patient  withdrawal
 
Subject Number  A number assigned to each patient who enrolls into the study  
Variable  A measured value or assessed response that is determined in 
specific assessments and used in data analysis to evaluate the  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 10 
Protocol No. CLCZ696BUS01   
  
 drug being tested in the study  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167670] of sacubitril/valsartan 
(LCZ696) versus enalapril on changes in NT -proBNP and  safety and 
tolerability of in- hospi[INVESTIGATOR_146444]/valsartan compared to enalapril 
in HFrEF patients who have been stabilized following hospi[INVESTIGATOR_146445] (ADHF)  
Brief title  In-hospi[INVESTIGATOR_146446]/valsartan vs. enalapril to assess changes in 
NT-proBNP through 8 weeks of treatment following an ep isode of acute 
decompensated heart failure.  
Sponsor and 
Clinical Phase  [COMPANY_001] 
Phase IIIb/IV  
Investigation type  Interventional  
Study type  Multicent er, randomized, double -blind, parallel group, active -controlled  
Purpose and 
rationale  The purpose of this study is to assess the effect of in- hospi[INVESTIGATOR_146447]/valsartan tablets vs. enalapril on time averaged proportional change 
in NT -proB NP in patients hospi[INVESTIGATOR_146448] 
(ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF)  
≤ 40%).  
Hospi[INVESTIGATOR_146449]- hospi[INVESTIGATOR_146450]. This 
increased risk justifies intervention with novel treatment strategies initiated 
prior to hospi[INVESTIGATOR_146451].  
Primary 
Objective(s)  The primary objective of this study is to assess the effect of in- hospi[INVESTIGATOR_146452]/valsartan tablets vs. enalapril on the time- averaged 
proportional change of NT -proBNP from baseline in patients who have been 
stabilized following hospi[INVESTIGATOR_146453] (left ventricular ejection fraction [LVEF] ≤ 40%). 
Weeks 4 and 8 will be included in the analysis (primary analysis time point).  
Secondary 
Objectives  To examine the effect of sacubitril/valsartan tablets vs. enalapril on change  in: 
• The proportional change in NT -proBNP from baseline to Week  8 
• Incidence of symptomatic hypotension during 8 weeks of  treatment  
• Incidence of hyperkalemia (Potassium >5.5 mEq/L) during 8 weeks of treatment  
• Incidence of angioedema during 8 weeks of  treatment  
• Biomarkers: high sensitivity -Troponin (hs -Troponin), urinary cGMP at  4 
and 8 weeks; and BNP:NT -proBNP  ratio 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167671] been stabilized, defined for this study as:  
 
• SBP ≥100mm Hg for the preceding 6 hours prior to randomization; no symptomatic  hypotension;  
• No increase (intensification) in i.v. diuretic dose within the last 6 
hours prior to randomization;  
• No i.v. inotropic drugs for 24 hours prior to randomization;  
• No i.v. vasodilators including nitrates within the last 6 hours prior to 
randomization  
All patients will need to meet all other inclusion and none of the exclusion 
criteria.  
Patients will be randomized to sacubitril/valsartan or enalapril. All patients 
randomized to sacubitril/valsartan will require a 36- hour wash- out from 
previous ACEi treatment prior to first do se of active study treatment. All 
randomized patients in the trial will remain hospi[INVESTIGATOR_146454] [ADDRESS_167672] dose of study medication. See 
section 3.1  for more 
details.  
At the end of the 8- week treatment period, all patients will enter a 4 - week 
follow up period on open label sacubitril/valsartan.  
Population  The study population will consist of male and female patients, ≥ 18 years of 
age, admitted to hospi[INVESTIGATOR_146455]. The goal is 
to randomize a total of approximately  882 patients to  sacubitril/valsartan   or 

 
 N o v arti s  
A m e n d e d Pr ot o c ol V er si o n 0 2 ( Cl e a n)  C o nfi d e nti al  P a g e 1 3  
Pr ot o c ol N o. C L C Z 6 9 6 B U S 0 1   
  
 e n al a pril i n a 1: [ADDRESS_167673] u d y a s:  
• S B P ≥ 1 0 0 m m H g f or t h e pr e c e di n g 6 h o ur s pri or  t o 
r a n d o mi z ati o n; n o s y m pt o m ati c  h y p ot e n si o n  
• N o i n cr e a s e (i nt e n sifi c ati o n) i n i. v. di ur eti c d o s e wit hi n l a st 6 
h o ur s pri or t o  r a n d o mi z ati o n  
• N o i. v. i n otr o pi c dr u g s f or 2 4 h o ur s pri or t o  r a n d o mi z ati o n  
• N o i. v. v a s o dil at or s i n cl u di n g nitr at e s wit hi n l a st 6 h o ur s pri or  t o 
r a n d o mi z ati o n;  
All p ati e nt s will n e e d t o m e et all ot h er i n cl u si o n a n d n o n e of t h e e x cl u si o n 
crit eri a.  
I n cl u si o n crit eri a  P ati e nt s eli gi bl e f or i n cl u si o n i n t hi s st u d y h a v e t o f ulfill all of t h e f oll o wi n g 
crit eri a:  
1.  P o s s e s s t h e c a p a cit y t o pr o vi d e writt e n i nf or m e d c o n s e nt w hi c h m u st b e 
o bt ai n e d b ef or e a n y a s s e s s m e nt i s  p erf or m e d.  
2.  P ati e nt s ≥ 1 8 y e ar s of a g e, m al e or  f e m al e.  
3.  C urr e ntl y h o s pit ali z e d f or A D H F. P ati e nt s wit h a di a g n o si s of a c ut e h e art 
f ail ur e  h a d  t o  h a v e  s y m pt o m s  a n d  si g n s  of  fl ui d  o v erl o a d  (i. e.  j u g ul ar  
v e n o u s  di st e nti o n,  e d e m a  or  r al e s  o n  a u s c ult ati o n  or  p ul m o n ar y  
c o n g e sti o n o n  c h e st x -r a y) at ti m e of  h o s pit ali z ati o n.  
4.  Eli gi bl e p ati e nt s will b e r a n d o mi z e d n o e arli er t h a n [ADDRESS_167674] at u s:  
 S B P ≥ 1 0 0 m m H g f or t h e pr e c e di n g 6 h o ur s pri or t o r a n d o mi z ati o n;  n o 
s y m pt o m ati c  h y p ot e n si o n  
 N o i n cr e a s e (i nt e n sifi c ati o n) i n i. v. di ur eti c d o s e wit hi n l a st 6 h o ur s 
pri or t o  r a n d o mi z ati o n  
 N o i. v. i n otr o pi c dr u g s f or 2 4 h o ur s pri or t o  r a n d o mi z ati o n  
 N o i. v. v a s o dil at or s i n cl u di n g nitr at e s wit hi n l a st 6 h o ur s pri or t o 
r a n d o mi z ati o n  
5.  L V E F ≤ 4 0 %  wit hi n  t h e  p a st  6  m o nt h s  (i n cl u di n g  c urr e nt  h o s pit ali z ati o n) 
u si n g  e c h o c ar di o gr a p h y,  m ulti  g at e d  a c q ui siti o n  s c a n  ( M U G A),  C T  
s c a n ni n g, M RI or v e ntri c ul ar a n gi o gr a p h y pr o vi d e d n o s u b s e q u e nt st u d y 
d o c u m e nt e d a n E F of  > 4 0 %.  
6.  El e v at e d N T -pr o B N P  ≥  1 6 0 0 p g/ m L  O R  B N P  ≥ 4 0 0  p g/ m L  d uri n g  c urr e nt 
h o s pit ali z ati o n  
E x cl u si o n crit eri a  P ati e nt s f ulfilli n g a n y of t h e f oll o wi n g crit eri a ar e n ot eli gi bl e f or i n cl u si o n i n 
t hi s  st u d y.  N o  a d diti o n al  e x cl u si o n s  m a y b e  a p pli e d  b y t h e  i n v e sti g at or,  i n  
or d er t o e n s ur e t h at t h e st u d y p o p ul ati o n will b e r e pr e s e nt ati v e of all eli gi bl e 
p ati e nt s.  
1. C urr e ntl y t a ki n g s a c u bitril/ v al s art a n t a bl et s or a n y u s e wit hi n t h e p a st 3 0 
d a y s.  
 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 14 
Protocol No. CLCZ696BUS01   
  
 2. Enrollment in any other clinical trial involving an investigational agent  or 
investigational  device.  
3. History of hypersensitivity, known or suspected contraindications, or 
intolerance to any of the study drugs, including ACEIs, ARBs, or 
Sacubitril (NEP  inhibitor)  
4. Patients with a known history of angioedema related to previous  ACE 
inhibitor or ARB therapy.  
5. Requirement of treatment with both ACE inhibitor and ARB.  
6. eGFR < 30 ml/min/1.73 m2 as measured by [CONTACT_146498] (MDRD) formula at  screening.  
7. Serum potassium > 5.2 mEq/L at  screening.  
8. Acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid or other major CV surgery; percutaneous coronary  intervention 
(PCI) or carotid angioplasty, within one month prior to Visit  1. 
9. Primary cause of dyspnea due to non- cardiac, non- heart failure  causes 
such as acute or chronic respi[INVESTIGATOR_146456]  
10. Intended coronary or carotid artery disease revascularization within the 6 
months after Visit  1. 
11. Implantation of a cardiac resynchronization therapy device (CRTD)  within 
the prior [ADDRESS_167675] or  with 
left ventricular assistance device (LVAD).  
13. Isolated right HF due to severe pulmonary  disease.  
14. Documented untreated ventricular arrhythmia with syncopal  epi[INVESTIGATOR_146457] [ADDRESS_167676] degree heart block without  a 
pacemaker.  
16. Presence of hemodynamically significant mitral, aortic, or  hypertrophic 
cardiomyopathy.  
17. History of malignancy of any organ system (other than localiz ed basal  cell 
carcinoma of the skin), treated or untreated, within the past year with a life expectancy of less than 1 year.  
18. Known hepatic impairment (as evidenced by [CONTACT_146499] > 3 mg/dL,  or 
increased ammonia levels, if performed), or history of cirr hosis with 
evidence of portal hypertension such as  varices.  
19. Pregnant or nursing (lactating) women, where pregnancy is defined  as 
the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory  test. 
20. Wom en of child- bearing potential, defined as all women physiologically 
capable of becoming pregnant, including women whose career,  lifestyle, 
or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by [CONTACT_146500], UNLESS they are using two birth control methods. The two methods can be a double barrier method (if accepted by [CONTACT_146501]) or a barrier method plus a 
hormonal  method 
• Adequate barrier methods of contraception include: diaphragm, condom (by [CONTACT_3969]), intrauterine device (copper or  hormonal), 
sponge or spermicide. Hormonal contraceptives include  any 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 15 
Protocol No. CLCZ696BUS01   
  
 marketed contraceptive agent that includes an estrogen and/or a 
progesterone agent.  
• Reliabl e contraception should be maintained throughout the study 
and for 7 days after study drug discontinuation.  
• Women are considered post -menopausal and not of child bearing 
potential if they have had 12 months of natural (spontaneous) 
amenorrhea with an appropriate clinical profile (e.g. age appropriate, 
history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol  < 
20 pg/mL or have had surgical bilateral oophorectomy (with or 
without hysterectomy) at le ast six weeks ago. In the case of 
oophorectomy alone, only when the reproductive status of the 
woman has been confirmed by [CONTACT_104].  
Investigational and reference therapy
 All eligible patients will be randomized to receive either  sacubitril/valsartan or 
enalapril. The following study treatment will be provided for the 8 - week 
double blind double dummy treatment period:  
• sacubitril/valsartan tablets + matching placebo or enalapril tablets + matching placebo.  
Open- label, sponsor -provided sacubitril/valsartan tablets will be provided for 
the open label extension.  
Efficacy 
assessments  Primary:  
Time -averaged proportional change from baseline in NT -proBNP. Weeks 4 
and 8 will be included in the analysis.  
Secondary:  
Proportional change in NT -proBNP from baseline to Week 8 
Biomarkers: hs -Troponin, urinary cGMP and BNP to NT -proBNP ratio 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 16 
Protocol No. CLCZ696BUS01   
  
 
Safety 
assessments   
 
Inc
idence of symptomatic hypotension  
Incidence of hyperkalemia (serum potassium ≥5.5 mEq/l)  
Incidence of angioedema In addition, safety will be assessed through  
physical exam, vital signs, laboratory evaluations, other adverse events and 
serious adverse events. The Data Monitoring Committee (DMC) will monitor 
safety.  
Data analysis  The primary hypot hesis to be tested is that the ratio of the geometric means  
of NT -Pro BNP (average of Weeks 4 and 8/baseline) for the 
sacubitril/valsartan tablets and enalapril groups are equal (H0) versus the 
ratio of the geometric means of NT - Pro BNP are not equal (Ha). For NT - 
proBNP, the time- averaged proportional change from baseline in a  
logarithmic scale will be analyzed using an analysis of covariance (ANCOVA) 
model using data from Weeks [ADDRESS_167677] - 
squared means from the ANCOVA model, and the corresponding two -sided 
95% confidence intervals will be provided. Baseline is Week  0. 
For NT -proBNP at Week 8, a proportional change from baseline in a 
logarithmic scale will be analyzed using an ANCOVA model with treatment as 
a fixed effect factor and the logarithmic baseline biomarker value as a 
covariate. The estimated treatment effect s in terms of ratios of geometric 
means, based on the least -squared means from the ANCOVA model, and the 
corresponding two- sided 95% confidence intervals will be provided. Baseline 
is Week 0. Week 4 will be used if the Week 8 value is missing.  
 
 
Inc
idences of symptomatic hypotension, hyperkalemia and angioedema will 
be calculated, along with relative risk of sacubitril/valsartan vs. enalapril and 95% confidence intervals of the relative risk.  
For biomarkers including BNP to NT -proBNP ratio, hs -Troponin, and urinary 
cGMP, the time- averaged proportional change from baseline in a logarithmic 
scale will be analyzed using an ANCOVA model using the data from Weeks [ADDRESS_167678] - 
squared means from the ANCOVA model, and the corresponding two- sided 
95% confidence intervals will be provided. Baseline is Week 0.  
For BNP to NT -proBNP ratio and urinary cGMP at Weeks [ADDRESS_167679] factor and the  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167680] -squared means from the ANCOVA 
model, and the corresponding two- sided 95% confidence intervals will be 
provided. Baseline is Week 0.  
Analyses of the secondary variables will be based on the full analysis set.  
The assessment of safety will be based primarily on the frequency of adverse events, SAEs, and laboratory abnormalities. Safety analyses will be 
performed based on the Safety Set. There will be no inferential analyses of the safety data.  
Assuming a significance level of 0.05 and 85% power, a sample size of [ADDRESS_167681] an 18% reduction in the geometric mean of the time- averaged proportional change from baseline (average of Weeks 4 
and 8) in NT -proBNP for the sacubitril/valsartan treatment group assuming a 
value of 0.[ADDRESS_167682] deviation of 0.85 
and a 25% rate of missing/non -evaluable samples.  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167683] heart failure 
(HF) and treatment costs for HF are approximately $31 billion annually (Go et al 2014) . 
Outcomes for patients after a hospi[INVESTIGATOR_146458]. The 1 - year 
mortality rate after a HF hospi[INVESTIGATOR_2138] 20- 30%, and this number has been relatively 
unchanged over the past decade ( Chen et al 2011, Loehr et al 2008) . 
The current state of treatments for patients hospi[INVESTIGATOR_135152]  (AHF) is 
focused around maintaining previously established guideline directed medical therapy, 
optimizing volume status, and initiating beta -blockers if indicated (Yancy et al 2013 , Gattis et 
al 2004) . Unfortunately, recent clinical trials employing a variety of ad ditional in -hospi[INVESTIGATOR_146459] -discharge outcomes ( Binanany et al 2005, Konstam  
et al 2007, Massie et al 2010 , O’Connor et al 2011) . Thus, therapeutic options to improve 
post- discharge survival free of recurrent HF hospit alizations for patients hospi[INVESTIGATOR_146460].  
In addition, while intravenous diuretics are nearly universally required for symptom relief during a HF hospi[INVESTIGATOR_059] (Gheorghiade et al 2005) , they activate the ren in-angiotensin - 
aldosterone system (RAAS) and sympathetic nervous system and may provoke renal dysfunction (Felker et al 2012) . Activation of the RAAS plays a fundamental role in the 
pathophysiology of HF (Braunwald 2013, Givertz 2001) , and although therapi[INVESTIGATOR_146461]  ( Yancy et al 2013, McMurray et al 2012) , they  
have not been extensively tested among patients hospi[INVESTIGATOR_146462]. Further reducing RAAS activation during the period following a HF hospi[INVESTIGATOR_146463]-discharge outcomes  for patients  with HF. 
Volume expansion and congestion during AHF leads to the synthesis and release of counter - regulatory natriuretic peptides from the myocardium: A -type natriuretic peptide (AN P) 
responding predominantly to atrial distention and B -type natriuretic peptide (BNP) to 
ventricular wall stress. The precursor molecule of BNP is a propeptide (proBNP108) that  when cleaved, results in the generation of the biologically active BNP and the  release in the 
circulation of a biologically inert aminoterminal fragment called N- terminal prohormone of 
Brain Natriuretic Peptide (NT -proBNP). This fragment is a largely stable peptide that can be 
measured in serum. Both BNP and NT -proBNP are useful to aid the diagnosis or exclusion of 
HF (Yancy et al 2013) . The PROTECT study was a small study ( N=151) that demonstrated 
that NT -proBNP guided therapy was superior to standard of care in reducing total 
cardiovascular events, i mproved quality of life and impact on cardiac remodeling in patients 
with chronic reduced ejection fraction ( Januzzi 2011) . A larger on- going study is looking to 
evaluate whether treatment directed therapy based on NT -proBNP levels will provide benefit 
to patients compared to standard of care in patients with reduced ejection fraction ( Felker  
2014) . 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167684] a worse prognosis ( Metra et al.  
2013) . Therefore, it is important to evaluate therapeutic strategies that can lead to superior 
reductions in NT-proBNP in patients hospi[INVESTIGATOR_146464].  
Sacubitril/valsartan combination tablet is an orally available, first in class, combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin receptor blocker that targets complementary pathways, RAAS inhibition via an Angiotensin II receptor blockade and natriuretic peptide augmentation via neprilysin inhibition. This novel agent may also hold promise in modifying the poor outcomes currently observed after a hospi[INVESTIGATOR_146465], especially in the initial high -risk post- hospi[INVESTIGATOR_146466]. 
 
Preliminary studies  
Sacubitril/valsartan, which is known in prior trials as LCZ696, has been evaluated for safety and efficacy in patients with chronic heart failure. The PARAMOUNT study was a randomized, double -blind, active -controlled phase  2 trial of 308 patients with HF with 
preserved ejection fraction (Left ventricular ejection fraction (LVEF) ≥45%) (Solomon et al  
2012) . Patients enrolled in the study received sacubitril/valsartan tablets titrated to 97/103 mg 
twice daily or valsartan titrated to 160 mg twice daily. The primary end po int of the study was 
change in NT -proBNP levels from baseline to 12 weeks. NT -proBNP levels were  
significantly reduced at 12 weeks in the sacubitril/valsartan group compared with the  valsartan group (sacubitril/valsartan: baseline, 783 pg/mL [95% CI 670 to 914], 12 weeks 605 pg/mL [95% CI512-714]; valsartan: baseline, 862 pg/mL [95% CI 733 -1012], 12 weeks  835 pg/mL [95% CI 710- 981]; ratio: sacubitril/valsartan /valsartan, 0.77, 95% CI 0.64 to 0.92, 
p=0.005. The sacubitril/valsartan combination was well tolerated and had a similar adverse effect profile to valsartan. The PARAGON -HF trial is now enrolling 4300 similar patients 
with chronic HF with preserved ejection fraction (LVEF ≥ 45%) to test whether the favorable effect of sacubitril/valsartan combinat ion tablet in reducing NT -proBNP seen in 
PARAMOUNT translates into a reduction in the composite end point of cardiovascular morbidity and total (first and recurrent) HF hospi[INVESTIGATOR_602].  
The PARADIGM -HF study was a large randomized, double -blind, active -controlled trial of 
8442 patients with symptomatic, chronic HF with reduced ejection fraction (LVEF ≤ 40%) (McMurray et al 2013, McMurray et al 2014) . Patients enrolled in the study started in a single 
blind sequential run- in phase with enalapril 10 mg twice daily and after a washout period of   
36 hours, went on to sacubitril/valsartan combination tablet at 97/103 mg daily to assess for safety and tolerability. Those patients who completed the run - in phase were then randomized 
and received sacubitril/valsartan combination tablet titrated to 97/[ADDRESS_167685] due to compelling evidence in favor of sacubitril/valsartan. Patients re ceiving sacubitril/valsartan combination 
tablet, compared to enalapril, were noted to have reduced risk of the primary outcome of 
composite of death from cardiovascular causes or hospi[INVESTIGATOR_10889] (HR0.80, 95% CI 0.73-0.87). The hazard  ratio for all-cause mortality  was 0.84 (95% CI, 0.76-0.93) and for 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 20 
Protocol No. CLCZ696BUS01   
  
hospi[INVESTIGATOR_146467] 0.79 (95% CI 0.71-0.89) (McMurray et al 2014) . In PARADIGM - 
HF, 8385 patients had a baseline NT -proBNP obtained. Results were consistent with the 
primary composite endpoint regardless of whether the NT -proBNP was less than or equal to 
the median values compared to higher than median values (USPI [INVESTIGATOR_146468], figure 4). 
Additionally, a subset of patients had biomarkers obtained at baseline, visit 3 (end of enalapril run-in), visit 5 (end of sacubitril/valsartan combination tablet run -in), 4 weeks after 
randomization, and at 8 months after randomization. The ratio of NT - proBNP to baseline 
levels was 25% lower in the sacubitril/valsartan combination tab let group compared to the 
enalapril group at [ADDRESS_167686] -randomization (both p<0.0001). Conversely, 
BNP levels were approximately 23% higher in the sacubitril/valsartan combination tablet group compared to the enalapril group at [ADDRESS_167687] -randomization (both 
p<0.0001). These findings are consistent with NT -proBNP not being a substrate of neprilysin, 
whereas BNP is a substrate of neprilysin; levels of BNP reflect the action of the drug whereas NT-proBNP levels reflect the effect  of the sacubitril/valsartan combination on the heart 
[PARADIGM -HF data on file, [Packer 2014]] . 
 
Table 1-1 Adverse reactions occurring at an incidence of >5% of patients in the 
double- blind period of PARADIGM -HF were as  follows:  
 
 Sacubitril/valsartan (N= 4203)  
% Enalapril (N=4220)  
 % 
Hypotension  18 12 
Hyperkalemia  12 14 
Cough  9 13 
Dizziness  6 5 
Renal failure/acute renal failure  5 5 
 
 
Angioedema occurred at rate of 0.5% in the sacubitril/valsartan arm compared to 0.2% in the enalapril arm (ENTRESTO USPI).  
The combination of sacubitril/valsartan was evaluated in a multicenter, randomized, double - 
blind, and parallel group design in heart failure patients with reduced ejection fraction to assess the safety and tolerability of two different titration re gimens ([STUDY_ID_REMOVED]). Patients 
were stratified  on low RAAS  inhibition  (whether  they were ACEi/ARB  naïve or receiving  
≤10 mg daily of enalapril or ≤ 160 mg daily of valsartan (or equivalent doses of other ACEi/ARBs)) or high RAAS inhibition stratum. This high RAAS inhibition stratum was defined as receiving > 10 mg daily of enalapril or > 160 mg daily of valsartan (or equivalent doses of other ACEi or ARBs). The patients underwent dosing with 50 mg BID during the open- label run -in period of 5 days, and then were randomized to titration of the  target dose  
of 97/103 mg twice daily over 6 weeks (conservative up- titration) c ompared to three weeks 
(condensed up -titration). 540 patients entered the run- in period and 498 were randomized.  
The primary endpoint was the proportion of patients experiencing pre -specified  adverse 
events (AEs) and pre -specified laboratory assessment outcomes. The results were presented at 
the European Society of Cardiology Heart Failure meeting in 2015. The combination of sacubitril/valsartan demonstrated an acceptable safety and tolerability profile regardless of  the 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 21 
Protocol No. CLCZ696BUS01   
  
up-titration regimen. After excluding non- adverse events discontinuations or death- related 
discontinuations, >76% of patients achieved and maintained the target dose of 97/103 twice 
daily for 12 weeks. Achievement of target dose was possible even in patients who required dose interruption or down- titration during the study period, and rates of AEs were generally 
lower than in the PARADIGM -HF trial. Hypotension occurred in 9.7% of the condensed 
regimen compared to 8.4% in the conservative regimen; renal dysfunction occurred in 7.3%  of condensed compared to 7.6% in the conservative regimen, hyperkalemia occurred in 7.7% 
in the condensed regimen compared to 4.4% in the conservative regimen and angioedema occurred in 0.0% in the condensed regimen compared to 0.8% in the conservative regimen.  
ENTRESTO™ (sacubitril/valsartan) received FDA approval on 07July2015. It is indicated to reduce the risk of cardiovascular death and hospi[INVESTIGATOR_146469] (NYHA class II -IV) and reduced ejection fraction. It is usually 
administered in conjunction with other heart failure therapi[INVESTIGATOR_146470]. The approved dosages are 24/26 mg, 49/51 mg, and 97/103 mg twice daily. During the prior clinical studies 24/26 mg, 49/51 mg, and 97/[ADDRESS_167688] study to examine sacubitril/valsartan combination tablet 
administration during ADHF and whether it can safely mitigate the adverse neuro -hormonal activatio n that persists and contributes to the unacceptably high adverse event rate currently 
observed in the first months after hospi[INVESTIGATOR_146471]-proBNP in this patient population. Importantly, although it is likely that c linical events 
(i.e., death, hospi[INVESTIGATOR_602], etc.) will occur in the patients randomized in the present study, there is not enough statistical power to assess the effect on these hard clinical outcomes and therefore this trial will not include differences in the rate of mortality or HF hospi[INVESTIGATOR_146472]. These endpoints will only be analyzed for the purpose of safety evaluation. 
 
1.2 Rationale for protocol amendment 
Amendment 2 (05Oct2017)  
On the basis of blinded review of the projected aggregated (enalapril and sacubitril/valsartan treatment groups combined) rate of missing samples for NTproBNP, this rate exceeds the initial trial assumption of 10%. The sample size has been increased to [ADDRESS_167689] of sacubitril/valsartan on NTproBNP after titration to dose level 3, a secondary endpoint has been added. 
  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 22 
Protocol No. CLCZ696BUS01   
  
Amendment 1 (28Jul2016)  
The protocol inclusion criteria have been modified to be more closely aligned with clinical 
practice in the [LOCATION_002] where patients with acute decompensated heart failure are often rapi[INVESTIGATOR_146473], with close follow -up. The protocol has been modified to include 
patients who are at least [ADDRESS_167690] longer hospi[INVESTIGATOR_602] (e.g. due to initial diagnostic uncertainty).  
Because a substantial proportion of patients who are stabili zed with medical therapy for acute 
decompensation heart failure are asymptomatic with a systolic blood pressure that remains predominantly within the range of 100 – 110 mm Hg, the inclusion  criterion  regarding 
systolic blood pressure has been lowered to ≥100 mmHg. The SBP stabilization period was also changed from 24 hours to 6 hours because a 6 hour window is considered an adequate period of time to establish stability.  
 
1.3 Changes to protocol 
Changes to specific sections in the protocol are shown in the track changes version of the protocol using the strike through font for deletions and red underlined for insertions. 
A copy of this amended protocol will be sent to the Institutional Review Boards 
(IRBs)/Independent Ethics Committees (IECs) and Health Author ities.  
The changes described in this amendment require IRB/IEC approval prior to implementation. In addition, since the changes herein do affect the informed consent, sites will be required to update and submit for approval a revised informed consent that takes into account the changes.  
 
1.[ADDRESS_167691] of in- hospi[INVESTIGATOR_146444]/valsartan 
vs. enalapril on time averaged proportional change in NT -proBNP in patients who have been 
stabilized following hospi[INVESTIGATOR_146474] (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).  
 
2 Study objectives  
2.1 Primary objective(s) 
The primary objective of this study is to assess the effect of in -hospi[INVESTIGATOR_146447]/valsartan vs. enalapril on the time -averaged proportional change of NT -proBNP 
from baseline in patients who have been stabilized following hospi[INVESTIGATOR_146475] (left ventricular ejection fraction [LVEF] ≤ 40%). Weeks 4 and 8 
will be included in the analysis (primary analysis time  point). 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167692] of sacubitril/valsartan vs. enalapril on: 
• The proportional change in NT-proBNP from baseline to Week 8 
• Incidence of symptomatic hypotension during 8 weeks of treatment  
• Incidence of hyperkalemia (Potassium >5.5 mEq/L)  during 8 weeks  of treatment  
• Incidenc e of angioedema during 8 weeks of treatment 
• Biomarkers: hs-Troponin (high sensitivity), urinary cGMP and BNP to NT-proBNP ratio 
at 4 and 8 weeks  
 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167693] been stabilized, defined for this study as:  
• SBP ≥100mm Hg for the preceding 6 hours prior to randomization; no symptomatic 
hypotension 
• No increase (intensification) in i.v. diuretic dose within last 6 hours prior to randomization 
• No i.v. inotropic drugs for 24 hours prior to randomization 
• No i.v. vasodi lators including nitrates within last 6 hours prior to  randomization 
 
All patients will need to meet all other inclusion and none of the exclusion criteria.  
In order to provide for a necessary 36 hour washout of prior ACEi treatment prior to receiving sacubitril/valsartan (known as LCZ696 in prior trials), the supplied blinded study drug for 
those allocated to sacubitril/valsartan will be placebo only until the [ADDRESS_167694] dose of study medication. Please see 
Figure  3-2. 
Patients will be randomized to sacubitril/valsartan or enalapril. Initial dose will be determined by [CONTACT_146502]. Study treatment will be titrated t o the 
Level #3 target doses of sacubitril/valsartan 97/[ADDRESS_167695] a 36 hour washout 
from study treatment prior to starting the ope n label extension to ensure that the blinding of  
the core study is maintained. To facilitate this washout, patients should take their final dose of 
study drug on the morning of their week 8 visit and then begin open label sacubitril/valsartan after 36 hours in the evening of week 8 visit + one day. 
All patients will start open label treatment on sacubitril/valsartan at their final dosing level during double blind treatment. However, at an investigator’s judgement, starting dose may be adjusted by [CONTACT_146503]. 
The intent of the open-label phase is to have the patients up- titrated to the desired dose level  
#3 (97/103 mg sacubitril/valsartan) based on clinical need and investigator judgement. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167696] randomization in 
the arm receiving the combination of the sacubitril/valsartan compared to the enalapril arm. In the current protocol, the primary endpoint of  NT-proBNP will be evaluated at both the 4 and 8 
week intervals to better assess the short -term benefit/risk ratio of sacubitril/valsartan  
compared to enalapril in patients who have been stabilized from an ADFH hospi[INVESTIGATOR_146476].  
The need for a 36- hour wash- out period is required per the FDA approved USPI [INVESTIGATOR_146477] a potential for increased risk for angioedema in patients who receive both an ACE inhibitor and the combination of sacubitril/valsartan. The requirement to stop the ARB is because there is an ARB contained within sacubitril/valsartan combination. The open- label 
period of 4 weeks provides the opportunity for every patient to receive sacubitril/valsartan and evaluate the change in NT -proBNP and other biomarkers in patients who had been previously 
receiving enalapril, while still being monitored for safety outcomes.  
 
 
 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167697] of care for RAAS blockade 
and is recommended by [CONTACT_146504] a 1A recommendation for all patients with CHF and reduced L VEF, unless ACEI -intolerant. As a well- studied ACEI in heart failure, 
enalapril has been selected as the comparator for this study with a target dose of 10 mg BID The 10 mg BID dose was the same target dosage studied in the SOLVD study and is the dose that was chosen   in the PARADIGM- HF trial.  
 
3.5 Purpose and timing of interim analyses/design adaptations 
Not applicable.  
 
3.6 Risks and  benefits 
All patients randomized to the sacubitril/valsartan treatment arm will be given matching placebo doses of both sacubitril/valsartan and enalapril on the day of randomization to fulfill the requirement for a 36 hour washout prior to sacubitril/valsartan treatment initiation. The first active dose of sacubitril/valsartan treatment will be the third dose of study drug received after randomization. The 36 hour wash out period is required to minimize the interaction between an ACEi and sacubitril in potentiating the development of angioedema. Patients randomized to the enalapril treatment arm do not require a washout, but will rec eive 
sacubitril/valsartan matching placebo in addition to active enalapril starting on the day of randomization. 
Since this is a double blind study, all study patients must remain in the hospi[INVESTIGATOR_93971] [ADDRESS_167698] dose of study medication even though the 36 hour wash out is only required for patients randomized to sacubitril/valsartan. This will allow for the first dose of active sacubitril/valsartan (third dose of study medication) to be administered in the hospi[INVESTIGATOR_146478] t hat the blind is maintained.  
All patients will be allowed to continue receiving the rest of their background cardiovascular (CV) medications. The risk to patients in this trial will be minimized by [CONTACT_146505]. A Data Monitoring Committee (DMC) will also monitor the study for all safety considerations, since this population represents a patient population who are being initiated on study drug during the same hospi[INVESTIGATOR_146479].  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 27 
Protocol No. CLCZ696BUS01   
  
Figure  3-2 36 hour washout  design  
 
 
 
RANDOMIZATION (0 hr)  
1st Dose  
Placebo  
 
   
 
   
 
   
 
    
 
 
RANDOMIZATION (0 hr)  
1st Dose 
Active Drug  [ADDRESS_167699] of their background cardiovascular 
(CV) medications. T he risk to patients in this trial will be minimized by [CONTACT_146506]. A Data Monitoring Committee (DMC) will also monitor the study for all safety considerations, since this population represents a patient population who are being initiated on study drug during the same hospi[INVESTIGATOR_146480].  
 
[ADDRESS_167700] of male and female patients, ≥ 18 years of age, presenting to the hospi[INVESTIGATOR_146455]. The goal is to randomize a total of approximately 882 patients to sacubitril/valsartan or enalapril in a 1:[ADDRESS_167701] been stabilized, defined for this study as: 
• SBP ≥100mm Hg for the preceding 6 hours prior to randomization; no symptomatic hypotension 
• No increase (intensification) in i.v. diuretic dose within last 6 hours prior to randomization 
• No i.v. inotropic drugs for 24 hours prior to randomization 
• No i.v. vasodilators including nitrates within last 6 hours prior to randomization; 
All patients will need to meet all other inclusion and none of the exclusion criteria.  Last dose of previous ACEi  
sacubitril/valsartan  
Screening  36 hour washout for sacubitril/valsartan treatment arm  [ADDRESS_167702] dose of previous ACEi  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167703] to fulfill all of the following criteria:  
1. Possess the capacity to provide written informed consent which must be obtained before 
any assessment is  performed.  
2. Patients ≥ [ADDRESS_167704] symptoms and signs of fluid overload (i.e. jugular venous distention, edema or rales on auscultation or pulmonary congestion on chest x -ray) at time of  hospi[INVESTIGATOR_059].  
4. Eligible patients will be randomized no earlier than 24 hours and up to ten days after presentation while still hospi[INVESTIGATOR_146481]:  
• SBP ≥100mm Hg for the precedin g 6 hours prior to randomization; no 
symptomatic  hypotension 
• No increase (intensification) in i.v. diuretic dose within last 6 hours prior to randomization 
• No i.v. inotropic drugs for 24 hours prior to randomization 
• No i.v. vasodilators including nitrates within last 6 hours prior to randomization 
 
5. LVEF ≤40% within the past 6 months (including current hospi[INVESTIGATOR_059]) using 
echocardiography, multi gated acquisition scan (MUGA), CT scanning, MRI or  ventricular angiography, provided no subsequent study documented an EF of >40%. 
6. Elevated NT -proBNP ≥ 1600pg/mL OR BNP ≥400 pg/mL during current  hospi[INVESTIGATOR_059].  
 
4.2 Exclusion criteria 
Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No additional exclusions may be applied by [CONTACT_17062], in order to ensure that the study population will be representative of all eligible patients.  
1. Currently taking sacubitril/valsartan tablets or any use within the past 30  days.  
2. Enrollment in any other clinical trial involving an investigational agent or investigational device.  
3. History of hypersensitivity, known or suspected contraindications, or intolerance to any 
of the study drugs, including ACEIs, ARBs, or Sacubitril (NEP inhibitor). 
4. Patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy.  
5. Requirement of treatment with both ACE inhibitor and  ARB.  
6. eGFR < 30 ml/min/1.73 m2 as measured by [CONTACT_146507] (MDRD) formula at  screening.  
7. Serum potassium > 5.2 mEq/L at screening.  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 29 
Protocol No. CLCZ696BUS01   
  
8. Acute coronary  syndrome, stroke, tr ansient  ischemic  attack;  cardiac,  carotid  or other 
major CV surgery; percutaneous coronary intervention (PCI) or carotid angioplasty, 
within one month prior to Visit 1. 
9. Primary cause of dyspnea due to non-cardiac, non- heart failure causes such as acute or 
chronic respi[INVESTIGATOR_17744]. 
10. Intended coronary or carotid artery revascularization within the 6 months after Visit 1. 
11. Implantation  of a cardiac resynchronization therapy  device  (CRTD)  within  the prior [ADDRESS_167705] or with left 
ventricular assistance device (LVAD).  
13. Isolated right HF due to severe pulmonary disease.  
14. Documented untreated ventricular arrhythmia with syncopal epi[INVESTIGATOR_128447] [ADDRESS_167706] degree heart block without a pacemaker.  
16. Presence of hemodynamically significant mitral, aortic or hypertrophic obstructive cardiomyopathy. 
17. History of malignancy of any organ system (other than loc alized basal cell carcinoma 
of the skin), treated or untreated, within the past year with a life expectancy of less than 
1 year.  
18. Known hepatic impairment (as evidenced by [CONTACT_146499] > 3 mg/dL, or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as varices.  
19. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. 
20. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by [CONTACT_146500], UNLESS they are using two birth control methods. The two methods can be a double barrier method (if accepted by [CONTACT_146508])  or a barrier method plus a hormonal method. 
• Adequate barrier meth ods of contraception include: diaphragm, condom (by [CONTACT_47446]), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progesterone agent. 
• Reliab le contraception should be maintained throughout the study and for 7 days 
after study drug  discontinuation. 
• Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an 
appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 20 pg/mL or have had surgical bilateral oophorectomy (with or 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 30 
Protocol No. CLCZ696BUS01   
  
without hysterectomy) at  least six weeks ago. In the case of oophorectomy  alone, 
only when the reproductive status of the woman has been confirmed by [CONTACT_146509].  
 
5 Treatment  
5.1 Protocol requested  treatment 
5.1.1  Investigational and control treatment  
 
Table 5-1 Investigational and comparator  treatment  
All eligible patients will be randomized to receive either sacubitril/valsartan or enalapril. The following study treatment will be provided: 
 
 
Treatment  Minimum 
dose Maximum 
dose Frequency  Admin. 
Route  
sacubitril/valsa rtan 24/26 mg  97/103 mg  BID oral 
sacubitril/valsartan matching 
placebo     oral 
Enalapril  2.5 mg  10 mg  BID oral 
Enalapril matching placebo     oral 
 
 
Table 5-2 Treatment Dose  Levels  
 
Dose Level  sacubitril/valsartan  Enalapril  
1 24/26 mg BID  2.5 mg BID  
2 49/51 mg BID  5.0 mg BID  
3 97/103 mg BID  10 mg BID  
Both sacubitril/valsartan and enalapril and their matching placebos will be packaged and labeled by [CONTACT_146510] s governing handling of investigationa l treatments, and will be dispensed by [CONTACT_5989].  
Matching placebo will also be needed for sacubitril/valsartan combination tablet and matching placebo for the enalapril for the first day of treatment to allow for the 36- hour washout 
required for patients randomized to the sacubitril/valsartan treatment arm.  
Each participating hospi[INVESTIGATOR_52121] a central supply kit containing dose levels 1 and 2 and their matching placebos. Bottles will be numbere d and assigned via an Interactive Web  Response System (IWRS). On the day of randomization (visit 2), the IWRS system will 
assign both a hospi[INVESTIGATOR_146482] a patient kit. 
Treatment for the day of randomization will be provided to the patients from the hospi[INVESTIGATOR_146483]. 
Treatment for the second day o f dosing onward will be provided from the patient kit which 
patients will take home upon discharge. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 31 
Protocol No. CLCZ696BUS01   
  
Patients not tolerating the target dose of sacubitril/valsartan 97/103 mg bid or enalapril 10 mg 
bid will be titrated down to the lower dose level (including active medication and matching 
placebos), at the investigator’s discretion, based on the defined safety and tolerability criteria. 
Sacubitril/valsartan dose or enalapril dose levels may be increased to the targeted desired dose 
level #3 of 97/103mg twi ce daily or enalapril 10 BID on an every 2 week basis or earlier if 
based on clinical need and investigator judgement. 
Patients not tolerating the target dose level #3 of sacubitril/valsartan 200 mg BID or enalapril 
10 mg BID will be titrated down to the lower dose level (including active medication and matching placebos), at the investigator’s discretion, based on the defined safety and tolerability criteria.  
This study is designed as a double-blind, double-dummy trial to ensure the blinding during the 
entire course of the study. To maintain the blinding, patients will be required to take their 
assigned active treatment tablet along with placebo matching the opposite treatment twice 
daily.  
All study sites will be provided with a Treatment Manual describing the treatment packaging and treatment instructions.  
 
5.1.2  Additional study  treatment  
 
Treatment  # of 
patients  Minimum 
dose  Maximum 
dose  Frequency  Admin.  
Route  
Open- label 
sacubitril/v 
alsartan  882 Dose level 
#1 (24/26  
mg) Dose l evel 
#3 (97/103  
mg) BID oral 
 
 
Open -label sacubitril/valsartan will be packaged and labeled by [CONTACT_146511], and 
will be dispen sed by [CONTACT_5989]. Open- label treatment will be provided for a 4 -week 
follow up. 
All patients will start open label treatment on sacubitril/valsartan at their final dosing level 
during double blind treatment. However, at an investigator’s judgement, starting dose may be adjusted by [CONTACT_146503]. 
The intent of the open-label phase is to have the    patients up-titrated to the desired dose level 
#3 (200 mg sacubitril/valsartan) based on clinical need and investigator judgement. 
 
5.2 Treatmen t arms  
Patients will be randomized in a 1:1 ratio to either sacubitril/valsartan or enalapril.  
 
5.[ADDRESS_167707] will be produced by [CONTACT_146512] D rug Supply 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 32 
Protocol No. CLCZ696BUS01   
  
Management using a validated system that automates the random assignment of treatment 
arms to randomization numbers in the specified ratio.  
Eligible patients will be randomized no earlier than 24 hours after presentation at the hospi[INVESTIGATOR_146484], while still hospi[INVESTIGATOR_057], via IWRS to one of the treatment arms. The investigator  or his/her delegate will contact [CONTACT_146513]. The IWRS will assign a randomization number to the patient, which will be used to link the patient to a treatment arm and will specify which  bottle from the centralized hospi[INVESTIGATOR_146485] a unique medication number for the first package of investigational treatment to be dispensed to the patient. The initial dose will be determined by [CONTACT_102]’s blood pressure at the time of the call to the  IWRS.  
The randomization numbers will be generated using the following procedure to ensu re that treatment assignment is unbiased and concealed from patients and investigator staff. A patient randomization list will be produced by [CONTACT_146514] a validated system that automates the random assignment of patient numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers. A separate medication list will be produced by [CONTACT_146515] a validat ed system that automates the random assignment of medication numbers to packs containing the investigational drug(s).  
Initial dose at randomization will be determined by [CONTACT_88087] (SBP). See Table 
5-3. 
Dose adjustments to lower dose levels may be made at any time at both scheduled and 
unscheduled visit only if clinically indicated for blood pressure control/tolerability reasons. Dose adjustments to increase dose levels may be made at any tim e at both scheduled and unscheduled visits based on clinical need or investigator judgement. 
Subsequent supplies of study drug will be assigned in the following manner. The investigator 
or his or her delegate will call the IWRS and provide the patient’s number. The IWRS will ask the caller whether there is a change in the dose level of the study drug. If the caller  indicates 
that there is no change in the dose level, the IWRS will provide the unique medication numbers of the study drug with the same dose le vel that was dispensed at the previous dispensing. If the caller indicates that the dose level has changed since the last dispensing, the IWRS will ask the caller which dose level should be dispensed. The caller will enter the dose level to dispense or whether no study drug should be dispensed (in case of study drug withdrawal). If applicable, the IWRS will provide the unique medication numbers for the  study drug supplies that should be dispensed at the new dose level.  
 
5.4 Treatment blinding 
Patients, investigator staff, persons performing the assessments and data analysts will remain 
blind to the identity of the treatment from the time of randomization until database lock, using 
the following methods: (1) Randomization data are kept strictly confidential until the time of unblinding, and will not be accessible by [CONTACT_146516], members of the DMC and the independent biostatistician assigned to the DMC. (2) The identity of the treatments will be  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 33 
Protocol No. CLCZ696BUS01   
  
concealed by [CONTACT_146517], labeling, 
and schedule of administration, appearance, taste and  odor. 
Unblinding will only occur in the case of patient emergencies (see Section 5.5.11) and at the 
conclusion of the study. 
 
5.[ADDRESS_167708] Number which is composed by [CONTACT_941] 4- digit site 
number (e.g., 0501, 0502 etc.) assigned by [CONTACT_64105] a [ADDRESS_167709] sequential number assigned 
by [CONTACT_093] (e.g., [ZIP_CODE], [ZIP_CODE], etc.). Hence a [ADDRESS_167710] Number will not be reused. 
Upon signing the informed consent form, the patient is assigned the next sequential number  
by [CONTACT_093]. The investigator or his/her staff will contact [CONTACT_146518]. The site will enter this number on the electronic case report form (eCRF) in the electronic data capture system  (EDC).  
 
5.5.[ADDRESS_167711]  day of  treatment  is  placebo only for 
patients randomized to the sacubitril/valsartan arm in order to facilitate the required 36- hour 
washout, the bottles assigned for the sacubitril/valsartan treatment arm will all contain placebos. Patients will receive their first [ADDRESS_167712] a 2 - part label. A unique 
randomization number is printed on each part of this label which corresponds to one of the 2 
treatment arms and a dose level. Investigator staff will identify the investigational treatment package(s) to dispense to the patient by [CONTACT_146519](s ). Immediately before dispensing the package to the patient, investigator staff will 
detach the outer part of the label from the packaging and affix it to the source document (Drug Label Form) for that patient’s unique subject number. 
 
5.5.3  Handling of study  treatment  
 
[IP_ADDRESS]  Handling of investigational and comparator treatment  
Investigational and comparator treatment must be received by a designated person at the study site, handled and stored safely and properly, and kept in a secured location to which only the inves tigator and designees have access. Upon receipt, all investigational and comparator 
treatment  should be stored  according  to the instructions specified  on the labels.  Clinical 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167713] of the shipment and dispensing of 
investigational and comparator treatment in a drug accountability log. Monitoring of drug accountability will be performed by [CONTACT_146520]. Patients will be asked to return all unused investigational or comparator treatment and packaging at the end of  the study or at the time of discontinuation  
of treatment.  
At the conclusion of the study, and as appropriate during the course o f the study, the investigator will return all unused investigational and comparator treatment, packaging, drug labels, and a copy of the completed drug accountability log according to the instructions provided by [CONTACT_146521]. 
 
[IP_ADDRESS]  Handling of other study  treatment  
Each study site will be supplied by [CONTACT_146522] - label sacubitril/valsartan for the 4 - 
week open -label  follow up period. The IWRS will need to be called to receive drug shipments 
prior to dispensing. 
The open- label sacubitril/valsartan packaging will have a 2 -part label. Investigator staff will 
identify the treatment package(s) to dispense to the patient b y contact[CONTACT_146523](s). Immediately before dispensing the package to the patient, 
investigator staff will detach the outer part of the label from the packaging and affix it to the source document (Drug Label Form) for that patient’s unique subject number. 
Open -label sacubitril/valsartan treatment must be received by a designated person at the study 
site, handled and stored safely and properly, and kept in a secured location to which only the 
investigator and designees have access. Upon receipt, all open -label sacubitril/valsartan 
treatment should be stored according to the instructions specified on the labels. Clinical supplies are to be dispensed only in accordance with the protocol. Medication labels will include storage conditions but no information about the patient except for the medication number. 
The investigator must maintain an accurate record of the shipment and dispensing of open- 
label sacubitril/valsartan treatment in a drug accountability log. Monitoring of drug accountability will be performed by [CONTACT_146524]. Patients will be asked to return all unused open -label treatment and 
packaging at the end of the study or at the time of discontinuation of treatment. 
At the conclusion of the study, and as appropriate during the course of the study, the 
investigator will return all unused open- label treatment, packaging, drug labels, and a copy of 
the completed drug accountability log according to the instructions provided by [CONTACT_146521].  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 35 
Protocol No. CLCZ696BUS01   
  
5.5.4  Instructions for prescribing and taking study  treatment  
All medication for the duration of the study will be provided by [CONTACT_5343]. Eligible patients  
will be randomized via IWRS to either sacubitril/valsar tan or enalapril. Patients randomized  
to the sacubitril/valsartan arm will receive sacubitril/valsartan matching placebo for the first day of treatment to fulfill the required 36 - hour wash- out period (in addition to enalapril 
matching placebo). Patients randomized to enalapril will not require a washout and will receive active treatment on the first day of treatment, in addition to sacubitril/valsartan 
matching placebo. The first day of dosing will be provided from a centralized hospi[INVESTIGATOR_146486] 1 and 2 and matching placebos. 
From the second day of treatment (third dose), patients will be provided with sufficient 
medication to last until the next scheduled visit. In order to adequately blind  the  study, patients will be required to take a total of two tablets (one tablet from the sacubitril/valsartan / sacubitril/valsartan matching placebo pack and one tablet from the enalapril/enalapril matching placebo pack) twice a day for the duration of the study. 
Initial dose at randomization will be determined by [CONTACT_88087] (SBP). 
• All patients with a systolic blood pressure (SBP) of ≥100 to ≤120 mm Hg will start at 
Dose level #1 (2.5 mg Enalapril or 24/26 mg sacubitril/valsartan, BID).  
• Patients with a SBP ≥ 120 mm Hg will start at dose level #2 (5 mg enalapril or 49/51 mg sacubitril/valsartan,  BID).  
• Patients will be titrated to the next dose level at Weeks 1 and 2 (Visits 3 and 4) with the goal of reaching the target dose for dose level #3 (10 mg enalapril or 97/103 mg sacubitril/valsartan, BID) by [CONTACT_5875] 2 (Visit  4). 
• Patients should be titrated to the next dose level at week 1 only if their SBP is >110 mm Hg and at week 2 if their SBP is > 100 mm Hg. 
Dose titration will proceed according to the following table:  
 
Table 5-3 Dose titration schedule based on SBP 
 
Visit Previous  dose  
level Systolic Blood 
pressure mm Hg*  Start/remain/tit 
rate to: Dose 
level #  
Baseline  (Visit  2) N/A ≥ 100  1 
N/A ≥120 2 
1 <110  1 
1 Week  (Visit  3)** 1 ≥110 2 
2 <110  2 
2 ≥110 3 
1 <100  1 
2 weeks  (Visit  4) 1 ≥100 2 
2 <100  2 
2 ≥100 3 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 36 
Protocol No. CLCZ696BUS01   
  
Visit Previous  dose  
level Systolic Blood 
pressure mm Hg*  Start/remain/tit 
rate to: Dose 
level #  
 
1  
<100   
1 
4 Weeks  (Visit  5) 1 ≥100 2 
2 <100  2 
2 ≥100 3 
1 <100  1 
6 Weeks  (Visit  6) 1 ≥100 2 
2 <100  2 
2 ≥100 3 
 
**Up titration may be done prior to the week 1 visit for patients who were started at dose  
level 1 who were previously on high dose RAS blockade (˃10 mg enalapril  total daily dose  or > 160 mg valsartan  total daily dose or equivalent doses of other ACEi or ARB).  
Dose adjustments to lower dose levels may be made at any time at both scheduled and unscheduled visits only if indicated for blood pressure control/tolerability reasons. 
Study medication should be taken with a glass of water with or without food. If the patient 
misses taking any study drug dose, he/she should take it as soon as possible, unless it is  almost time for the following scheduled dose. In this case, the patient should skip the missed dose and return  back  to his/her regular  study drug administration schedule.  
All dosage prescribed and dispensed to the patient and all dose changes during the study must be recorded in the IWRS and on the Dosage Administration Record eCRF. 
The investigator should promote compliance by [CONTACT_146525]’s safety and the validity of the study. The patient should be instructed to contact [CONTACT_087]/she is unable to take the study treatment as pr escribed for any reason.  
All patients that complete 8 weeks of treatment will proceed with a 4 - week follow up on 
open- label sacubitril/valsartan. All patients will have the wash out in order to maintain the 
blinding of the core study. To facilitate this w ashout, patients should take their final dose of 
study drug on the morning of their week 8 visit and then begin open label sacubitril/valsartan after 36 hours in the evening of week 8 visit + one day. All patients will start open label treatment on sacubit ril/valsartan at their final dosing level during double blind treatment. 
However, at an investigator’s judgement, starting dose may be adjusted by [CONTACT_146503]. 
The intent of the open-label phase is to have the patients up- titrated to    the d esired dose level  
#3 (200 mg sacubitril/valsartan) based on clinical need and investigator judgement. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167714] dose ( dose level #3),  
but patient tolerability and safety must be taken into account. 
If the tolerability issues are not alleviated despi[INVESTIGATOR_146487] - titration by [CONTACT_30560], the 
investigator may lower the study drug dose further to the next lower level for 1 to a maximum 
of 4 weeks, up to temporary withdrawal of the study drug. Again, once stable, the patient 
should be re -challenged with up -titration to the next higher dose level in an attempt to bring 
back the patient gradually to the target study drug dose level (dose level #3). The investigator may choose the next dose level for down - or up- titration according to his or her clinical 
judgment. The IWRS should be contact[CONTACT_146526]’s study drug dose level, including in cases of temporary and permanent withdrawal of the study drug, and to obtain the medication numbers of the study drug supplies required for the new study drug dose level.  
In some instances, according to the safety and tolerability criteria and the investigator’s judgment, dose level  1 or 2 could be maintained if he/she considers that the  patient’s 
condition would not allow any further up- titration to the target dose of study medication (dose 
level #3). In this case it would be acceptable to maintain the patient at dose level  #1 or   level  
#2, whichever is the higher and tolerated dose level by [CONTACT_102], but reasons for not getting to dose level #3 need to be clearly described in the eCRF.  
 
Study drug restart after temporary treatment interruption  
Study drug should be reintroduced in those who temporarily discontinue it as soon as 
medically justified in the opi[INVESTIGATOR_871]. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 38 
Protocol No. CLCZ696BUS01   
  
Once the investigator considers the patient’s condition appropriate for receiving the study 
drug, the investigator should re -start the patient on the study drug at the most appropriate and 
allowable dose level per his/her medical judgment. If tolerated, the patient should be up- 
titrated up to dose level 3 every 1 to 4 weeks, as per the investigator’s judgment. Patients re - started on the study dru g will retain their original randomization and study identification 
numbers. Should the patient not tolerate the re -start study drug dose level, he/she may be 
down- titrated again (if appropriate) or discontinue the study medication.  
Study visits should occur as close as possible to the pre -defined visit schedule. The timeframe 
between the regular visits should be maintained as scheduled, irrespective of the number of unscheduled visits that may be performed in between, according to the visit and time schedule described in Table 6 -1. 
Any changes in the study drug dose level, including temporary/permanent withdrawal or re - start of the study drug, must be recorded on the Dosage Administration Record eCRF and registered in the IW RS. 
In case of pregnancy discovered during the study, the patient should be instructed to stop taking the study drug immediately.  
 
5.5.6  Rescue  medication  
Guidance on handling hyperkalemia, hypotension, and renal dysfunction are provided to investigators in the appendices. Patients may receive open - label (non -study medications) 
ACEIs and/or ARBs during the study ONLY if the study medication has been discontinued 
either temporarily or permanently. A [ADDRESS_167715] the patient to notify the study site about any new medications he/she takes after the patient was enrolled into t he study. All medications, procedures and significant non -drug therapi[INVESTIGATOR_014] (including physical therapy and blood transfusions) 
administered after informed consent must be recorded on the Concomitant medications or Surgeries and Medical Procedures eCRF.  
 
ACEIs and ARBs:  
Patients’ pre -study ACEIs/ARBs will be replaced with the study medication.  
The concomitant use of open- label ACEIs or ARBs is strictly prohibited while the patient is 
receiving study medication. If the investigator believes that addition of an ACEI or ARB is necessary, then study drug must be discontinued. Study medication should be stopped [ADDRESS_167716], 
consideration should be given to adding this therapy rather than an ACEI or and ARB, while 
monitoring renal function. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 39 
Protocol No. CLCZ696BUS01   
  
Other heart failure and cardiovascular medication  
If a patient’s condition warrants any change in concomitant heart failure or cardiovascular 
medications, changes may be made at the investigator’s discretion.  
Oral diuretics may be used and may be adjusted throughout the study duration at the  discretion of the investigator. 
 
Medications known to raise potassium levels  
Potassium sparing diuretics, potassium supplements, aldosterone antagonists, and any other medications known to raise potassium levels should be used with caution while the patient is 
receiving study medication due to the increased possibility of occurrence of hyperkalemia. Potassium levels should be monitored regularly especially in those who are receiving these medications.  
Concomitant administration of renin inhibitors, such as aliskiren, is prohibited. 
 
Phosphodiesterase -5 (PDE -5) inhibitors  
PDE -5 inhibitors should be used with caution while the patient is receiving study medicatio n 
due to the increased possibility of occurrence of hypotension. 
 
Nesiritide and intravenous nitrates  
The concomitant admission of sacubitril/valsartan with nesiritide and intravenous nitrates has not been studied. Concomitant use of nesiritide will not be permitted during the study. 
 
Other medications  
Bile acid sequestering agents such as cholestyramine or colestipol are prohibited to avoid interference with study drug absorption. 
 
5.5.[ADDRESS_167717] be discontinued under the following circumstances: 
• Withdrawal of consent 
• Pregnancy  
• Use of prohibited concomitant medication  
• Any protocol deviation that constitutes a risk to the patient  
• Investigator believes that continuation of study drug may be detrimental to the patient’s 
well-being  
 
Study medication may be discontinued at the investigator’s discretion if any of the following 
occur:  
• Any severe suspected drug related  AE 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 40 
Protocol No. CLCZ696BUS01   
  
• Suspected occurrence of angioedema. A patient with any signs or symptoms of clinically 
significant  angioedema should be thoroughly evaluated  by [CONTACT_146527] a reason for discontinuation of study medication.  
• Depending on the serum  potassium, blood pressure,  or eGFR,  patients  may need  to have 
their study drug dose or the dose of another concomitant medication reduced or discontinued; or, if appropriate, have potentially contributing agents adjusted. Refer to appendices for treatment guidelines for hyperkalemia, hypotension or renal dysfunction, respectively.  
In the case of study drug discontinuation, patients should remain in the trial and attend follow- up visits. If the patient refuses, he/she should be contact[CONTACT_146528]-up health status information in place of protocol- specified visits unless the patient expressly 
refuses such contacts.  
The investigator must notify the IWRS of any study drug discontinuation and record it on the drug administration eCRF. 
 
5.5.[ADDRESS_167718] to  follow -up 
For patients whose status is unclear because they fail to  appear for study visits without stating 
an intention to withdraw, the investigator should show "due diligence" by [CONTACT_121944], family or family physician as agreed in the informed consent and by [CONTACT_146529] t o contact [CONTACT_102], e.g. dates of telephone calls,  
registered letters, etc. A patient should not be formally considered lost to follow -up until 
his/her scheduled end of study visit would have occurred. 
 
5.5.[ADDRESS_167719] often, study treatment discontinuation and knowledge  of the possible treatment assignments are sufficient to treat a study patient who presents with an emergency condition. Emergency treatment code breaks are performed using the IWRS. When the investigator contacts the system to break a treatment code for a patient, he/she must 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 41 
Protocol No. CLCZ696BUS01   
  
provide the requested patient identifying information and confirm the necessity to break the 
treatment code for the patient. The investigator will then receive details of the investigational 
drug treatment for the specified patient and a fax or email confirming this information. The system will automatically inform the [COMPANY_001] monitor for the site and the Clinical Trial Lead (CTL) that the code has been broken. 
It is the investigator’s responsibility to ensure that there is a procedure in place in case of an 
emergency. The investigator will inform the patient how to contact [CONTACT_5657]/her backup in cases of emergency when he/she is unavailable. The investigator will provide protocol number, study treatment name [CONTACT_90228], patient number, and instructions for contact[CONTACT_90194] ( or any entity to which it has delegated responsibility for 
emergency code breaks) to the patient in case an emergency treatment code break is required at a time when the investigator and backup are unavailable.  
 
5.5.[ADDRESS_167720] the patient completion in the  IWRS.  
 
5.5.13 Early study  termination  
The study can be terminated at any time for any reason by [CONTACT_5343]. Should this be necessary , 
the patient should be seen as soon as possible and treated as a prematurely withdrawn patient. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the patie nt’s interests. The 
investigator will be responsible for informing the Institutional Review Board/Independent Ethics Committee (IRBs/IECs) of the early termination of the  trial. 
 
6 Visit schedule and  assessments  
All assessments are listed in Table 6 -1. Assessments that are to be reported in the clinical 
database are marked with an ‘x’. Assessments that will only be reported in the source documentation are marked with a ‘s’. Patients should be seen for all visits on the designate d 
day or as close to it as possible. 
The screening period may begin following an admission to hospi[INVESTIGATOR_146488]. Clinical 
assessments performed during a patient’s hospi[INVESTIGATOR_059], prior to signing of informed consent, may be used for Visit 1/Screening. Eligible patients may be randomized once it is confirmed that they meet all inclusion criteria and none of the exclusion criteria.  
 
Patients may be contact[CONTACT_146530] [ADDRESS_167721] the patient should be 
recorded in the source documentation. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 42 
Protocol No. CLCZ696BUS01   
  
Unscheduled visits for safety/medication evaluation/unscheduled assessments are permitted at 
any time during the study.  
 
 
Table 6-1 Assessment  schedule  
 
Visit number  1 2 3 4 5 6 7 8 9 
Phase  screening  Treatment  4 week 
f/u- 
titration  4 week f/u
 
Week    1 2 4 6 8 10 ~12 
Day -10 to -1 1 7 14 28 42 56 70 84 
Informed consent  s         
Inclusion/exclusion 
criteria  x x        
Demography/ 
medical history  x         
Heart failure and CV 
disease history  x         
ECG x         
Physical exam  s   s    
(cardiac 
related 
only)   s  s 
Height  x x        
Weight  x x x x x x x x x 
Vital signs  x x x x x x x x x 
Waist/hip 
circumference  x         
HF signs and symptoms and 
NYHA x x x x x x x x x 
HF and CV 
medications  x x8 x x x x x  x 
Conmeds  x x x x x x x x x 
AE/SAE  x x x x x x x x x 
Pregnancy test  x x4   x  x  x 
Plasma BNP or NT - 
proBNP  x9 x x x x  x  x 
Plasma/serum 
biomarkers1  x x x x  x  x 
Spot urine 
biomarkers2  x x x x  x  x 
Urinalysis   x        
Chemistry  x x x x x  x x6 x 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 43 
Protocol No. CLCZ696BUS01   
  
Visit number  1 2 3 4 5 6 7 8 9 
Phase  screening  Treatment  4 week 
f/u- 
titration  4 week 
f/u 
Week    1 2 4 6 8 10 ~12 
Day -10 to -1 1 7 14 28 42 56 70 84 
Hematology  x x     x   
Hemoglobin A1C   x        
IWRS call  x x x x x x x x x 
Randomization   x        
Dispense treatment   x x x x x x5 x  
Drug accountability    x x x x x x x 
Angioedema 
assessment  x x x x x x x x x 
Study completion – 
randomized 
treatment        x   
Study completion – 
open label period          x 
Post study 
completion follow 
up3         s3 
 1 includes cardiac, renal, and drug mechanism of action biomarkers  
2 include urinary mar kers such as cGMP.  
3Health status phone call 4 weeks after study completion (16 weeks).  
4Urine pregnancy test will be done at Visit 2 at the local laboratory.  
5At week 8, patients will receive open label sacubitril/valsartan and be instructed to not take s tudy 
medication on the day of the final visit in order to fulfill the washout requirement  
6Limited chemistry panel.  
 
8CV medications will be recorded at time of hospi[INVESTIGATOR_2345].  
[ADDRESS_167722] the study 
completion page for the screening visit, demographics, inclusion/exclusion, and serious adverse event (SAE) data collected. Adverse events that are not SAEs will be followed by [CONTACT_90200]. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 44 
Protocol No. CLCZ696BUS01   
  
6.2 Patient demographics/other baseline characteristics 
Patient demographic and baseline characteristic data to be collected on all patients include: 
date of birth, age, sex, race, ethnicity and source of patient referral. Relevant medical history/current medical condition data includes data collected up to the point in which informed consent is signed. Where possible, diagnoses and not symptoms, will be recorded. HF medications will be recorded in eCRFs separately from other medications. Likewise, detailed HF history and other relevant CV medical history will be recorded on eCRFs separately from other medical history.  
 
6.3 Treatment exposure and compliance 
Compliance will be assessed by [CONTACT_1755]/or study personnel at each visit using pi[INVESTIGATOR_146489]. This information should be captured in the 
source document at each visit. Patient compliance should be at least 80% during the double - 
blind treatment period. The investigator and/or study personnel will counsel the patient if  
compliance is below 80%. Study drug accountability will also be determined by [CONTACT_146531].  
Duration of double-blind study drug exposure will be calculated based upon the start and stop dates recorded in the eCRF.  
 
6.4 Efficacy 
The efficacy end points are: 
Primary:  
Time -averaged proportional change from baseline in NT-proBNP. Weeks 4 and 8 will be 
included in the analysis. Secondary:  
• The proportional change in NT-proBNP from baseline t o Week  8 
• Biomarkers: hs-Troponin, urinary cGMP and BNP to NT-proBNP ratio 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167723] heart sound. NYHA classification will be assessed and scored at each  visit.  
 
 
 
6.4.3  Biomarkers  
BNP or NT -proBNP will be obtained in all patients by [CONTACT_146532] 1 to 
determine eligibility. NT -proBNP will be obtained in all patients using the central laboratory 
at Visits 2, 3, 4, 5 and 7  (randomization, weeks 1, 2, 4, and  8),       and at the end of the  open label extension, Visit 9 (Week 12). 
In addition, biomarker measurements will be obtained from serum and plasma samples at 
Visits 2, 3, 4, 5, 7 and 9 (randomization, 2, 4, 8 and 12 weeks), to determine effects of treatment on biomarkers of CV, CHF or renal risk. Spot urine will be collected at Visits 2, 3, 4, 5, 7 and 9 (randomization, weeks  1, 2, 4, 8 and 12) to measure urinary  cGMP.  
The selected biomarkers to be studied will be those believed to be relevant to the 
pathophysiology of the disease processes of heart failure and renal dysfunction. Biomarkers studies may include, but are not limited to those accessing cardiac and renal benefit or biomarkers related to the study drug mechanism of action such as: 
• Neurohormones BNP and NT-proBNP  
• hs-Troponin (will not be measured at Week 2) 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 46 
Protocol No. CLCZ696BUS01   
  
• ur
inary cGMP  
Evaluation of Neprilysin measurement at baseline as a predictor of clinical outcome may be 
added depending on availability of a validated assay and sample handling requirements. The list may be changed or expanded further as new relevant biomarkers may be discovered  during this study and after its completion. As such, serum and plasma will be bio - banked for 
analysis of yet to be identified diagnostic biomarkers. Details of sample collection, handling and shipment will be provided to investigators in the laboratory manual.  
 
6.4.[ADDRESS_167724] for the 
evaluation of therapeutic agents in a heart failure population. 
 
6.5 Safety  
  
 
• I
ncidence of symptomatic  hypotension 
• Incidence of hyperkalemia (Potassium >5.5 meq/l)  
• Incidence of  angioedema  
Safety assessments will consist of monitoring and recording of all adverse events and serious adverse events, evaluation of hematology, blood chemistry and urine values, regular measurement of vital signs and the performance of physical examinations. 
 
6.5.1  Physical  examination  
A complete physical exam will be performed at Visits 1, 7 and 9 (screening, weeks 8 and 12). It will include the examination of general appearance, skin, neck, eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, and vascular and neurological examinations. If indicated based on medical history, and/or sy mptoms, rectal, external 
genitalia, breast and pelvic exams will be performed. The Visit 4 (Week 2) physical exam will only be a cardiac care exam.  
Information for all physical examinations must be included in the source documentation at the study site. Significant findings that are present prior to the start of the study drug must be included in the Relevant Medical History/Current Medical Conditions screen on the patient’s eCRF. Significant findings made after informed consent which meet the definition of  an 
adverse event must be recorded on the Adverse Event eCRF. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167725]/hip  circumference 
Height in centimeters if possible will be measured at Visits [ADDRESS_167726]/hip circumference to the 
nearest centimeter will be measured at Visit  1. 
 
6.5.4  Angioedema  
Angioedema is a type of abrupt swelling that occurs under the skin and/or mucous membranes 
and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, including the genitalia and intestines. Severe cases may be associated with airway 
compromise. Although, the mechanism is not fully understood, bradykinin has  been  implicated as the putative mediator. Therefore, medications that raise the levels  of  endogenous bradykinin by [CONTACT_146533], such as ACE, aminopeptidase P, and NEP, may result in this potentially dangerous side effect. All suspected cases of angioedema, regardless of suspected causality, must be reported. The Angioedema Assessment forms must be completed and the Clinical Trial Lead or their designee must be 
notified. 
If the angioedema event meets SAE criteria, the investigator must ensure that an SAE form is 
completed and submitted to [COMPANY_001] Drug Safety and Epi[INVESTIGATOR_623]. 
 
6.5.5  Laboratory  evaluations  
The local hospi[INVESTIGATOR_146490]. If eligibility laboratory assessments were not done during the patient’s hospi[INVESTIGATOR_059], samples should be collected and sent to the local laboratory. A central laborat ory will be used for analysis of all collected specimens from baseline through the final 
visit. Details on the collections, shipment of samples and reporting of results by [CONTACT_146534]. R esults fr om the local 
hospi[INVESTIGATOR_146491]. 
Clinically notable laboratory findings are defined in Appendix 1. 
Local laboratory assessments may be performed on an as -needed basis for unscheduled visits. 
Laboratory values that exceed the boundaries of a notable laboratory abnormality must be 
commented on by [CONTACT_146535]'s eCRF and additional laboratory evaluations should be performed, as judged appropriate by [CONTACT_093]. If the laboratory abnormality induces clinical signs or symptoms, or requires therapeutic intervention, then the diagnosis or medical condition must be entered on the AEs screen  of  the  patient's  eCRF.  If  the  laboratory  abnormality is  the  primary  reason  for an 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167727] be followed. Likewise, if the laboratory 
abnormality lead s to discontinuation from the study drug (temporarily or permanently), the 
patient must be followed until the abnormality resolves or until it is judged to be permanent. This investigation may include continued monitoring by [CONTACT_146536].  
 
[IP_ADDRESS]  Hematology  
Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, and 
platelet count will be measured at Visits 1 (local lab), 2 and 7 (central lab). Hemoglobin A1c 
will be measured at Visit 2 (central lab).  
 
[IP_ADDRESS]  Clinical  chemistry  
Assessments required for eligibility that need to be measured at Visit 1 include creatinine, potassium, and total bilirubin. Blood urea nitrogen (BUN), glucose, creatinine, total bilirubin, AST (SGOT), ALT (SGPT), alkaline phosphatase, sodium, potassium, chloride, calcium ,  total protein, albumin, uric acid, and lipid profile will be measured at Visits 2, 3, 4, 5, 7 and 9 (central  lab). 
 
[IP_ADDRESS]  Urinalysis  
Dipstick -test determination of specific gravity, pH, blood, total protein, bilirubin, ketones, and 
leukocytes will be measured at Visit 2 (central lab). If dipstick is positive, a qualitative microscopic determination, including white blood cells  high power field (WBCs/HPF) and red 
blood cells high power field (RBCs/HPF) will be performed. 
 
6.5.[ADDRESS_167728] (hCG) 
performed at Visit 1 (local lab) a nd Visits 5, 7 and 9 (central lab). In addition, these patients 
will have a urine pregnancy test conducted in the hospi[INVESTIGATOR_146492] 2. If any of these 
tests are positive at Visits [ADDRESS_167729] for t he evaluation of 
patients with heart failure.  
 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 49 
Protocol No. CLCZ696BUS01   
  
 
 
7 Safety  monitoring 
7.1 Adverse  events 
Study drug includes the investigational drug under evaluation and the comparator drug or 
placebo that is given during any phase of the study. Medical conditions/diseases present 
before informed consent are only considered AEs if they worsen after informed consent. Abnormal laboratory values or test results constitute AEs only if they induce clinical sig ns or symptoms, are considere d clinically significant, or require  therapy.  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167730] be recorded on the Adverse Events CRF with the following information. 
1. the severity grade [mild, moderate,  severe]  
2. its relationship to the study drug(s) (suspected/not suspec ted) 
3. its duration (start and end dates or if continuing at final exam)  
4. whether it constitutes a serious adverse event (SAE)  
Unlike routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements; see Section 7.2.2. 
All AEs should be treated appropriately. Treatment may include one or more of the following: 
no action taken (i.e. further observation only); study drug dosage adjusted/temporarily interrupted; study drug permanently discontinued due to this AE; concomitant medication given; non- drug therapy given; patient hospi[INVESTIGATOR_057]/patient’s hospi[INVESTIGATOR_18533]. The 
action taken to treat the AE should be recorded on the Adverse Event CRF. 
Once an AE is detected, it should be followed unti l its resolution or until it is judged to be 
permanent, and assessment should be made at each visit (or more frequently, if necessary) of 
any changes in severity, the suspected relationship to the study drug, the interventions required to treat it, and the outcome. 
[COMPANY_001] may request additional information on specific adverse events of interest and may 
make requests to perform additional diagnostic tests to further assess the safety profile of the study medications. Such information may include diagnostic  procedure reports, disch arge 
summaries, autopsy reports, and other relevant information that may help in assessing the reported adverse event. All additional information will be de -identified prior to collection by 
[CONTACT_146521].  
Information about common side effects already known about the investigational drug can be found in the Investigator’s Brochure (IB) or will be communicated between IB updates in the form of Investigator Notifications. This information will be included in the patient informed consent and should be discussed with the patient during the study as needed. 
 
7.2 Serious adverse  events  
7.2.1  Definition of  SAE 
An SAE is defined as any adverse event (appearance of or worsening of any pre - existing) 
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the following criteria:  
• is fatal or  life-threatening  
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth  defect  
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]:  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 51 
Protocol No. CLCZ696BUS01   
  
• routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition (specify what this includes) 
• elective or pre- planned treatment for a pre -existing condition th at is unrelated to the 
indication under study and has not worsened since signing the informed consent  
• treatment on an emergency outpatient basis for an event not fulfilling any of  the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
• social reasons and respi[INVESTIGATOR_064]’s general  condition 
• is medically significant, i.e. defined as an event that jeopardizes the patient or may require medical or surgical  intervention. 
All malignant neoplasms  will be assessed as serious under “medically significant” if other 
seriousness criteria are not met.  
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetic ally might have caused death if more severe .  
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_76593]. Examples of such events are intensive treatment in an emergency room or at hom e for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_6536] . 
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reacti on. 
All AEs (serious and non- serious) are captured on the CRF, SAEs also require individual 
reporting to DS&E as per section 7.2.2. 
 
7.2.[ADDRESS_167731] at the study institution.  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167732] assess the relationship to study drug, complete the SAE Report 
Form in English, and send the completed, signed form by [CONTACT_87109] 24 hours to the local [COMPANY_001] Drug Safety and  Epi[INVESTIGATOR_623] (DS&E) Department. The telephone number of the 
contact [CONTACT_146537]&E, specific to the site, are listed in the investigator folder provided to each site. The original copy of the SAE Report Form and the fax confirmati on sheet must be kept with the case report form documentation at the study site. 
Follow- up information is sent to the same person to whom the original SAE Report Form was 
sent, using a new SAE Report Form stating that this is a follow -up to the previously reported 
SAE and giving the date of the original report. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, wheth er the blind was broken or not, and whether the patient continued or withdrew f rom study participation.  
If a SAE is unexpected, i.e., the event is not previously documented in the Investigator’s Brochure (new occurrence) and is suspected to be related to the [COMPANY_001] study drug, this event is considered a Suspected Unexpected Serious  Adverse Reaction (S[LOCATION_003]R) . A 
DS&E associate may urgently require further information from the investigator for Health Authority reporting purposes. In general, it is [COMPANY_001] policy to unblind S[LOCATION_003]Rs for regulatory reporting. If the unblinding shows that t he [COMPANY_001] drug is involved, [COMPANY_001] 
will issue an Investigator Notification (IN) to inform all investigators participating in any study with the same drug that this S[LOCATION_003]R has been reported. In addition, S[LOCATION_003]Rs will be 
collected and reported to the compe tent authorities and relevant ethics committees as per 
[LOCATION_002] regulatory requirements in the  [LOCATION_003].  
An external independent DMC will be appointed and will review efficacy and safety data of the ongoing trial on a regular basis. DMC opi[INVESTIGATOR_146493]. 
 
7.3 Reporting of study treatment errors including misuse/abuse 
Table 7-1 Guidance for capturing the study treatment  errors including  
misuse/abuse  
Treatment  error 
type Document in Dose 
Administration  (DAR) 
eCRF  (Yes/No)  Document in AE 
eCRF  Complete SAE form  
Unintentional  study 
treatment  error  Yes Only if  associated with  
an AE Only if associated with an 
SAE 
Misu se/Abuse  Yes Yes Yes, even if  not associated  
with a  SAE 
 
 
7.[ADDRESS_167733] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 53 
Protocol No. CLCZ696BUS01   
  
the birth, and the presence or absence of any birth defects, congenital abnormalities, or 
maternal and/or newborn complications. 
Pregnancy must be recorded on the Pharmacovigilance Pregnancy Form and reported by [CONTACT_90210][INVESTIGATOR_066]. Pregnancy follow- up should be recorded on the same form and should include an assessment of  the 
possible relationship to the study treatment.  
Any SAE experienced during the pregnancy and unrelated to the pregnancy must be reported on a SAE form. 
 
7.5 Reporting angioedema-like events  
It is important that the investigator pays special attention to any  swelling or edema that may 
resemble angioedema or angioedema- like events that may be reported by [CONTACT_1962]. If such an 
event occurs, the investigator will complete an Adjudication Questionnaire for an Angioedema- like Event form (provided by [CONTACT_5343]) to su mmarize the event, its treatment, 
and its ultimate outcome and communicate this report to [COMPANY_001] as soon as possible. Follow - 
up reports must be communicated to [COMPANY_001] as soon as new information regarding the event becomes available. All hospi[INVESTIGATOR_146494]. 
Occasionally, the investigator may be contact[CONTACT_146538] -like event. The investigator 
or his/her delegated staff must complete the required report forms and supply the required medical records for such events, regardless of whether the investigator views the event in question as angioedema or not. 
All angioedema reports will be forwarded to an angioed ema a djudication committee by 
[CONTACT_18653].  
Submission of an angioedema report is not a substitution for the submission of a SAE report. 
If an angioedema- like event satisfies the definition of a SAE, the investigator must submit a 
SAE report in addition to the Adjudication Questionnaire for an Angioedema-like Event. 
 
8 Data review and database management  
8.1 Site monitoring 
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol  and (e)CRFs with the investigators and their staff. 
During the study, [COMPANY_001] employs several methods of ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness of  patient records, the accuracy of entries on the (e)CRFs, the 
adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications.  Key study personnel must be available to assist the field monitor during these 
visits. Continuous remote monitoring of each site’s data may be performed by a centralized monitor. Additionally, a central analytics organization may analyze data & id entify risks &  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167734] maintain source documents for each patient in the study, consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on CRFs must be traceable to these source documents in the patient's file. The investigator must also keep the original informed consent form signed by  [CONTACT_102] (a signed copy is given to the patient).  
The investigator must give the monitor access to all relevant source documents to confirm  their consistency with the eCRF entries . [COMPANY_001] monitoring standards require  full  
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the (e)CRFs are performed according to the study-specific monitoring plan. No information in source documents about the identity of the patients will be  disclosed. 
 
8.2 Data collection 
Designated investigator staff will enter the data required by [CONTACT_5374] (eCRFs) using fully validated software that conforms to [ADDRESS_167735], which employs the Anatomical Therapeutic Chemical classification system. Medical history/current medical conditions and AEs will be coded using the Medical dictionary for regulatory activities (MedDRA)  terminology. 
Laboratory samples will be processed centrally and the results will be sent electronically to the designated  CRO.  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 55 
Protocol No. CLCZ696BUS01   
  
Randomization codes and data about all study drug dispensed to the patient and all dosage 
changes will be tracked using an Int eractive Voice Response System (IWRS). The system will 
be supplied by a vendor, who will also manage the IWRS database. The IWRS database will 
be sent electronically to the designated CRO.  
At the conclusion of the study, the occurrence of any emergency code breaks will be determined after return of all code break reports and unused drug supplies to [COMPANY_001]. The occurrence of reportable protocol deviations will be determined. After these actions have been completed and the database has been declared to be complete and accurate, it will be locked and the treatment codes will be unblinded and made available for data analysis. Any changes to the database after that time can only be made by [CONTACT_146539] U nit Head.  
 
8.4 Data Monitoring Committee 
An external data monitoring committee (DMC) independent of [COMPANY_001] will be appointed to review the incidence of the pre -specified clinical events including major cardiac  events, 
serious adverse events, the rate and distribution of adverse events , and relevant laboratory findings on an ongoing basis. If it is deemed necessary for internal decision making due to patient safety, an interim analysis will be conducted by [CONTACT_146540]. 
The membership of the DMC and the responsibilities of the DMC and [COMPANY_001] will be 
defined in a separate document entitled ‘Data Monitoring Committee Charter’. The DMC Charter will include information about data flow, purpose and timing of DMC meetings, guidance in the deci sion making process, communication strategy, procedures for ensuring 
confidentiality, procedure to address conflicts of interest and statistical monitoring  guidelines. 
 
8.5 Adjudication Committee 
It is important that the investigator pays special attention to any swelling or edema that may 
resemble angioedema or angioedema- like events that may be reported by [CONTACT_1962]. There will 
be a separate eCRF for angioedema events. If such an event occurs, the investigator will 
complete an Adjudication Questionnaire for an Angioedema- like Event form (provided by 
[CONTACT_5343]) to summarize the event, its treatment, and its ultimate outcome and communicate this report to [COMPANY_001] as soon as possible. Follow -up reports must be communicated to 
[COMPANY_001] as soon as new information regarding the event becomes available. All hospi[INVESTIGATOR_146495]. 
Occasionally, the investigator may be contact[CONTACT_146541] -like event. The investigator 
or his/her delegated staff must complete the required report forms and supply the required medical records for such events, regardless of whether the investigator views the event in question as angioedema or not. 
All a ngioedema reports will be forwarded to an angioedema adjudication committee by 
[CONTACT_18653].  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page [ADDRESS_167736] a two -sided 
alternative hypothesis, employing  a significance level of  0.05. 
Efficacy, safety, and other data will be summarized. For continuous variables, summary statistics (mean, standard deviation, median, 25th and 75th percentiles, interquartile range, minimum, and maximum) at each time point and  for change from baseline to each time point 
will be reported by [CONTACT_1570]. 
 
9.1 Analysis  sets 
The following patient sets will be used for the statistical reporting and analyses: 
The Randomized Set will consist of all randomized patients. 
The Full Analys is Set (FAS) will consist of all randomized patients with the exception for 
those patients who have not been qualified for randomization and have not received study 
drug, but have been inadvertently randomized into the study. Following the intent -to-treat 
principle, patients will be  analyzed  according  to  the  treatment  to  which  they  were assigned  at randomization.  Efficacy  variables  will  be  analyzed  based  on  the  FAS   as  the  primary  set. 
The Safety Set (SAF) will consist of all randomize d patients who received at least one dose of 
study drug. Patients will be included in the analysis according to the treatment actually received. The Safety Set will be used for the analyses of safety variables.  
The Per -Protocol (PP) set will be a subset of  the FAS which will consist of the patients who 
do not have major deviations from the protocol procedures in the double -blind study stage. 
Major protocol deviations will be pre -specified prior to unblinding treatment codes for 
analyses. This supplemental e fficacy set will be used to support the primary analysis  results.  
 
9.[ADDRESS_167737] dose of 
randomized study medication, including the matching placebos, unless specified otherwise in the protocol. 
Summary statistics will be provided by [CONTACT_146542], including age, age group (<65 years vs. ≥65 years; <75 years vs. ≥75 years), sex, race, ethni city, weight, height, body mass index (BMI), category of prior CHF 
medication, prior HF hospi[INVESTIGATOR_059], NYHA class, NT-proBNP, BNP, and vital signs. BMI 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 57 
Protocol No. CLCZ696BUS01   
  
will be calculated as weight (kg) / height2 (m2) from the collected height and weight at Visit 1 
(Screening Visit). Continuous variables will be summarized using n, mean, standard deviation, 
median, 25th and 75th percentiles, interquartile range, minimum, and maximum. Geometric 
means will be used to summarize the NT -proBNP results. Categorical variables will be 
summarized using frequency and percentage. 
The Randomized Set and FAS will be the patient sets for the above analyses. 
 
9.[ADDRESS_167738] deviation, median, 25th and 75th percentiles, interquartile range, 
minimum, and maximum. Additionally, the number and percentage of patients will be summarized by [CONTACT_146543]. 
Concomitant medications and significant non- drug therapi[INVESTIGATOR_014], prior to and after the 
randomization date will be summarized by [CONTACT_18671], preferred term, and treatment 
group. 
The number and percentage of patients on different HF background medications will be 
tabulated by [CONTACT_146544] d ouble-blind stage. 
The Safety Set will be used for the above analyses.  
 
9.4 Analysis of the primary variable(s) 
9.4.1  Variables  
The primary efficacy variable is the time -averaged proportional change from baseline in NT - 
proBNP. Weeks 4 and 8 will be included in the analysis (primary analysis time point).  
 
9.4.2  Statistical model, hypothesis, and method of  analysis 
The primary hypothesis to be tested is that the ratio of the geometric means of NT -proBNP 
(average of Weeks 4 and 8/baseline) for the sacubitril/valsartan and enalapril groups are equal 
(H0) versus the ratio of the geometric means of NT-proBNP are not equal (Ha). 
For NT -proBNP, the time -averaged proportional change from baseline in a logarithmic scale 
will be analyzed using an analysis of covariance (ANCOVA) model using data from Weeks [ADDRESS_167739]-squared means from the ANCOVA model, and the corresponding two - sided 95% 
confidence intervals will be provided. Baseline is Week 0. 
The change from baseline log -transformed NT -proBNP will be calculated as log (post -dose 
value) – log (baseline value). Geometric means (presented as a ratio t o baseline) will be 
calculated by [CONTACT_146545] -transforming the LS means based on the ANCOVA model. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 58 
Protocol No. CLCZ696BUS01   
  
9.4.3  Handling of missing values/censoring/discontinuations  
The analysis will be performed based on all available data in the FAS and based on likelihood 
method with an assumption of missing at random for missing data. 
 
9.4.4  Supportive  analyses 
T-tests comparing treatment groups using change from log (baseline) to log (Week 8) values 
and log (Week 4) values will be performed. 
In addition to the primary analysis, the primary efficacy variable will also be analyzed using 
the same analysis model in the PP Set as supportive. 
 
9.[ADDRESS_167740] -squared means from the ANCOVA model, and the 
corresponding two -sided 95% confidence intervals will be provided. Baseline is Week 0 . 
Week 4 will be used if the Week 8 value is missing. 
Incidences of symptomatic hypotension, hyperkalemia and angioedema will be calculated, 
along with the relative risk of sacubitril/valsartan vs. enalapril and 95% confidence intervals  
of the relative  risk. 
For biomarkers including BNP to NT -proBNP ratio, hs -Troponin, and urinary cGMP, the 
time-averaged proportional change from baseline in a l ogarithmic scale will be analyzed using 
an ANCOVA model using the data from Weeks [ADDRESS_167741] -squared means from the ANCOVA 
model, and the corresponding two- sided 95% confidence intervals  will  be  provided. 
Baseline is Week  0. 
For BNP to NT -proBNP ratio and urinary cGMP at Weeks [ADDRESS_167742] -squared means from the ANCOVA model, and the corresponding 
two-sided 95% confidence intervals will be provided. Baseline is Week 0. 
Analyses of the secondary variables will be based on the FAS. 
 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 59 
Protocol No. CLCZ696BUS01   
  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 60 
Protocol No. CLCZ696BUS01   
  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 61 
Protocol No. CLCZ696BUS01   
  
 
9.5.3  Other safety  variables  
The safet y and tolerability assessments are listed below: 
• AEs and  SAEs  
• Sitting systolic, diastolic BP, and pulse  pressure 
• Heart  rate 
• Laboratory  values  
The assessment of safety will be based primarily on the frequency of adverse events, SAEs, 
and laboratory abnormal ities. Other safety data will be summarized as appropriate.  
The incidence of treatment -emergent adverse events (new or worsened) will be summarized 
by [CONTACT_92869], preferred term, severity, and relationship to study drug. In 
addition, the incidence of death, SAEs, and AEs leading to discontinuation will be summarized separately by [CONTACT_146546].  
Laboratory data will be summarized by [CONTACT_146547] (baseline to most extreme post -baseline value), by [CONTACT_146548] (mean, median, standard deviation, 25th and 75
th 
percentiles, interquartile range, minimum and maximum) and by [CONTACT_146549].  
Data from other tests (e.g., ECG or vital signs) will be listed, notable values will be flagged, and any other information collected will be listed as appropriate. 
Safety analyses will be performed based on the Safety Set. There will be no infer ential 
analyses of the safety data.  
 
 
9.5.5  Pharmacokinetics  
Not Applicable. 
 
9.5.6  Pharmacogenetics and pharmacogenomics  
Not applicable.  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 62 
Protocol No. CLCZ696BUS01   
  
9.5.7  Biomarkers  
See Sections 9.4 and Section 9.5 for a description of the methods used to analyze the 
biomarkers.  Any other biomarkers collected but not specifically mentioned in Sections 9.4 or 9.5 will be analyzed in the same  manner.  
 
9.5.8       PK/PD  
Not applicable.  
 
9.6 Interim analyses  
No interim analysis is planned. 
 
9.7 Sample size  calculation 
Assuming a  significance level of 0.05 and 85% power, a sample size of [ADDRESS_167743] an 18% reduction in the geometric mean of the time -averaged proportional 
change from baseline (average of Weeks 4 and 8) in NT -proBNP for the sacubitril/vals artan 
treatment group assuming a value of 0.[ADDRESS_167744] deviation of 0.85 and a 25% rate of missing/non -evaluable samples. The estimates are based 
on the day [ADDRESS_167745] deviati on estimate is 
supported by [CONTACT_146550].  
The assumption of a 18% reduction in the geometric mean for NT -proBNP for the 
sacubitril/valsartan treatment group vs. the enalapril group is consistent with NT -proBNP 
results seen in PARADIGM (26% and 25% re lative reduction of sacubitril/valsartan vs. 
enalapril at Week 4 and Month 8 respectively), PARAMOUNT (23% relative of sacubitril/valsartan vs. valsartan at Week 12) and RELAX -AHF (19% relative reduction of 
serelaxin vs. placebo at Day 2).  
 
Table 9-[ADDRESS_167746] e size and power for various rate of  reduction in 
sacubitril/valsartan group given alpha  =0.05:  
 
Change  Common  Relative reduction in  Change in GM for  Power  Non- Total sample  
in GM for 
enalapril  SD GM for 
sacubitril/valsartan  sacubitril/valsartan 
group   evaluable 
rate size after 
adjusting for  
  group compared to     non- 
  enalapril group     evaluable  
      rate 
.95 .85 15% .81 85% 10% 1096 
.95 .85 15% .81 90% 10% 1280 
.95 .85 18% .78 85% 10% 736 
.95 .85 18% .78 90% 10% 860 
.95 .85 18% .78 85% 25% 882 
.95 .85 20% .76 85% 10% 582 
.95 .85 20% .76 90% 10% 680 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 63 
Protocol No. CLCZ696BUS01   
  
10 Ethical  considerations  
10.1 Regulatory and ethical compliance 
This clinical study was designed and shall be implemented and reported in accordance with  
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC, US CFR 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Decla ration of Helsinki.  
 
10.2 Informed consent procedures 
Eligible patients may only be included in the study after providing written (witnessed, where required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if applicable, after 
such consent has been provided by a legally acceptable representative(s) of the patient. In cases where the patient’s representative gives consent, the patient should be informed about the study to the extent possible given his/her understanding. If the patient is capable of doing so, he/she should indicate assent by [CONTACT_146551] a separate assent form. Informed consent must be obtained before conducting any study -specific procedures (i.e. all of the procedures described in the protocol). 
The process of obtaining informed consent should be documented in the patient source documents. 
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent 
form that complies with the ICH GCP guideline and regulatory requirements and is  
considered appropriate for this study. Any changes to the proposed consent form suggested by 
[CONTACT_90219]/IEC, and a copy of the approved version must be provided to the [COMPANY_001] monitor after IRB /IEC  approval. 
Women of child bearing potential should be informed that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study and agree t hat in order to participate in the study they must adhere to the contraception requirement for the duration of the study. If there is any question that the patient will not reliably comply, they should not be entered in the study. 
In the event that [COMPANY_001] wants to perform testing on the samples that are not describ ed in  
this protocol, additional Institutional Review Board and/or Ethics Committee approval will be 
obtained. 
 
10.3 Responsibilities of the investigator and IRB/IEC 
Before initiating a trial, the investigator/institution should obtain approval/favorable opi[INVESTIGATOR_3078] n 
from the Institutional Review Board/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates,  subject  recruitment procedures (e.g., advertisements) and any other written information to be provided to patients. Prior to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Quality Assurance representatives, designated 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 64 
Protocol No. CLCZ696BUS01   
  
agents of [COMPANY_001], IRBs/IECs, and regulatory authorities as required. If an inspection of the 
clinical site is requested by a regulatory authority, the investigator must inform [COMPANY_001] 
immediately that this request has been made.  
 
10.4 Publication of study protocol and results 
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicly accessib le database such as clinicaltrials.gov. In addition, upon study completion and 
finalization of the study report the results of this trial will be either submitted for publication and/or posted in a publicly accessible database of clinical trial results.  
 
[ADDRESS_167747] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_6669]/IEC and health authorities, where required, it cannot be implemented. All significant protocol deviations will be recorded and reported in the CSR. 
 
11.[ADDRESS_167748] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC prior to implementation. Only amendments that are intended to eliminate an apparent  immediate hazard to patients may be implemented immediately provided the Health Authorities are subsequently notified by [CONTACT_6670]/IEC is notified. Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any patient included in this study, even if this action represents a deviation from the protocol. In such cases, the reporting requirements identified in section 7 Safety Monitoring should be followed. 
 
12 References  
Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV and Miller LW. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. Journal American Medical Association 2005;294:1625-33. 
Braunwald E. Heart failure. Journal American Col lege Cardiology Heart Failure 2013;1:1-20. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 65 
Protocol No. CLCZ696BUS01   
  
Chen J, Normand SL, Wang Y, and Krumholz HM. National and regional trends in heart 
failure hospi[INVESTIGATOR_146496], 1998 -2008. Journal 
American Medical Association. 2011;306:1669-78. 
Felker GM, et al. Rationale and Design of the GUIDE-IT study. Journal American College 
Cardiology Heart Failure 2014;2:457-65. 
Felker GM and Mentz RJ. Diuretics and Ultrafiltration in Acute Decompensated Heart Failure. 
Journal American College o f Cardiology 2012;59:2145-2153. 
Gattis WA, O’Conner CM, Gallup DS, Hasselblad V and Gheorghiade M. Predischarge initiation of carvedilol in patients hospi[INVESTIGATOR_118962]: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT -HF) trial. Journal American College of Cardiology 2004;43:1534-41. 
Gheorghiade M, Zannad F, Sopko G, Klein L, Pi[INVESTIGATOR_135164], Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G and Tavaz zi L. Acute heart failure syndromes: current 
state and framework for future research. Circulation 2005;112:3958-68. 
Givertz MM. Manipulation of the renin-angiotensin system. Circulation 2001;104:E14-8. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MF, Dai S, Ford ES, Fox 
CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, 
Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, 
Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, 3
rd, Moy CS, 
Mussolino ME, Meumar RW, Nichol G, Pandey DK, Paynter, NP, Reeves MJ, Sorlie, Stein J, 
Towfighi A, Turan TN, Virani SS, Wong ND, Woo D and Turner MB. Heart disease and 
stroke statistics – 2014 update: A report from the American Heart Association. Circulation 
2014;129:e28-e292. 
Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, 
Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregor y SA, Uthamalingam S, Semigran MJ. Use 
of amino- terminal pro -B-type natriuretic peptide to guide outpatient therapy of patients with 
chronic left ventricular systolic dysfunction. Journal American College of Cardiology 2011;58:188. 
Konstam MA, Gheorghiade M, Burnett JC, Jr., Grinfeld L, Maggioni AP, Swedberg K, 
Udelson JE, Zannad F, CookT, Ouyang J, Zimmer C and Orlandi C. Effects of oral tolvaptan in patients hospi[INVESTIGATOR_85066]: the EVEREST Outcome Trial. Journal American Medical Asso ciation 2007;297:1319-31. 
Loehr LR, Rosamond WE, Change PP, Folsom AR and Chambless LE. Heart Failure Incidence and Survival (from the Atherosclerosis Risk in Communities Study). The American Journal of Cardiology 2008;101:1016-1022. 
Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, 
Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM and Dittrich HC. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. The New England Journal of Medicine 2010;363:1419-28. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 66 
Protocol No. CLCZ696BUS01   
  
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, 
Solomon SD, Swedberg K and Zile MR. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin -converting en zyme inhibition in patients with chronic systolic 
heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PAR ADIGM - 
HF).. European Journal of Heart Failure 2013;15:1062-73. 
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, 
Solomon SD, Swedberg K and Zile MR. Baseline characteristics and treatment of patients in Prospective comp arison of ARNI with ACEI to Determine Impact on Global Mortality and 
morbidity in Heart Failure trial (PARADIGM -HF). European Journal of Heart Failure 2014. 
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K and Zile MR. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine 2014;371:993-1004. 
McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, 
Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GYH, Maggioni AP, Parkhomenko A, Pi[INVESTIGATOR_146497], Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepi[INVESTIGATOR_87463] J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Jour nal 2012;33:1787-1847. 
Metra M. et al. Effect of Serelaxin on cardiac, renal and hepatic biomarkers in the Relaxin in 
Acute Heart Failure  (RELAX -AHF) Development Program, Correlation with Outcomes. 
Journal of the American College of Cardiology 2013;61:196-206 
O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, 
Heizer GM, Komajda M, Massie BM, McMurray JJV, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Claus ell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, 
Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Met ra M, Mittal S, Oh B -H, Pereira NL, Ponikowski P, Tang WHW, Tanomsup 
S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F and Califf RM. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine 2011;365:32-43. 
Solomon SD, Zile M, Pi[INVESTIGATOR_88082] B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, 
Takeuchi M, Gong J, Lefkowitz M, Packer M and McMurray JJV. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-1395. 
von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC, Jr. and Krum 
H. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel 
therapeutic concepts to combat heart failure. Circulation Heart Failure2013;6:594-605. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 67 
Protocol No. CLCZ696BUS01   
  
Yancy C, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, 
Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ and Wilkoff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240-e327. 
 
13 Appendix 1: Clinically notable laboratory  values 
Clinically notable laboratory abnormalities for selected tests based on a percent c hange from 
baseline:  
 
Hematology  
RBC  count >50% increase, >20%  decrease  
Hemoglobin >50% increase, >20%  decrease  
Hematocrit  >50% increase, >20%  decrease  
WBC  count >50% increase, >50%  decrease  
Platelet  count >75% increase, >50%  decrease  
 
Blood Chemistry  
ALT  (SGPT)  >150% increase  
AST  (SGOT)  >150% inc rease  
BUN  >50% increase  
Creatinine  >50% increase  
Total bilirubin  >100% increase  
CPK  >300% increase 
Alkaline phosphatase >100% increase  
Potassium >20% increase, >20%  decrease  
Chloride >10% increase, >10%  decrease  
Calcium  >10% increase, >10%  decrease  
Uric acid >50% increase  

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 68 
Protocol No. CLCZ696BUS01   
  
14 Appendix 2: Treatment guidelines for hyperkalemia (serum 
potassium greater than or equal to 5.5  mEq/L) 
General principles  
Elevation of potassium levels above the predefined values should be repeated and confirmed 
before any action is taken.  
Any patient who experiences a potassium level ≥ 5.5 mEq/L confirmed by [CONTACT_146552], repeated checks of potassium concentration (beyond that prescribed in the protocol) until it is clear that the potassium concentration is stable and not rising into the range of concern (≥ 5.5 mEq/L).  
Patients with elevated potassium value will be managed according to the corrective actions outlined below and the investigator’s clinical judgement. Hyperkalemia should be followed until resolution. 
Recommended corrective action for management of hyperkalemia 
Serum potassium > 5.3 and less than or equal to 5.5 mEq/L  
• Confirm potassium concentration in a non- hemolyzed  sample  
• Reinforce low potassium diet and restriction of food/drinks with high potassium content 
(e.g. orange juice, mel on, bananas, low- salt substitutes  etc.) 
• Review medical regimen (including dietary supplements and over-the- counter medications) 
for agents known to cause hyperkalemia. Consider reduction in dose or discontinuation of 
these agents:  
• Aldosterone antagonists ( if they are believed to be the most likely cause of  hyperkalemia)  
• Potassium-sparing diuretics (e.g. amiloride and triamterene) including in combination products with thiazide or loop diuretics  
• Potassium supplements, e.g., potassium chloride 
• Salt substitute s 
• Non-steroidal anti- inflammatory drugs  (NSAIDs)  
• Cyclo -oxygenase- 2 (COX -2) inhibitors 
• Trimethoprim and trimethoprim-containing combination products, such as Bactrim
® and 
Septra® (trimethoprim/sulfamethoxazole fixed  combination) 
• Herbal  Supplements: 
• For example, Noni juice, alfalfa ( Medicago sativa), dandelion ( Taraxacum officinale ), 
horsetail  (Equisetum arvense ), nettle  (Urtica  dioica),  milkweed,  lily of the valley,  Siberian 
ginseng, hawthorn berries  
• Repeat serum potassium  measurement within 3 to 5 days 
• If serum  potassium remains  > 5.3 and ≤ 5.5 mEq/L,  regularly  monitor serum  potassium 
levels to ensure stability (suggested once monthly) 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 69 
Protocol No. CLCZ696BUS01   
  
• Consider down- titration of study medication, according to investigator’s medical 
judgment. 
 
Serum potassium > 5.5 and < 6.0 mEq/L  
• Confirm potassium concentration in a non- hemolyzed  sample  
• Consider down- titration or temporarily discontinue study drug according to investigator 
medical  judgment. 
• Apply all measures outlined for serum potassium > 5.3 and ≤ 5.5 mEq/L  
• Repeat serum potassium measurement after 2 -3 days 
• If serum potassium < 5.5 mEq/L, consider resumption of study drug at lower dose with 
repeat potassium within 5  days 
 
Serum potassium greater than or equal to 6.0 mEq/L  
• Immediately discontinue study drug 
• Confirm potassium concentration in a non- hemolyzed  sample  
• Urgently evaluate patient and treat hyperkalemia as clinically  indicated  
• Apply all measures outlined for serum potassium > 5.3 and < 6.0 mEq/L 
• If serum potassium < 5.5 mEq/L, consider resumption of study drug at lower dose with repeat potassium within 5 days 
 
15 Appendix 3: Guidelines for the management of blood 
pressure  
Guidelines  
1. Investigator should monitor blood pressure closely  
2. If symptomatic hypotension occurs:  
a. Correct any treatable cause, e.g.  hypovolemia 
b. If hypotension persists, any antihypertensive drug and non- disease-modifying drugs, 
such as diuretics, CCBs, nitrates, and α -blockers, should be down- titrated  or 
stopped first before down-titration of the study drug is considered 
3. If hypotension persists, the study drug should be down- titrated or even temporarily 
withdrawn. The dose re-challenge and medication adjustment guidelines described in 
Section 5.5.5 should be adhered to as much as possible. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 70 
Protocol No. CLCZ696BUS01   
  
16 Appendix 4: Guidelines for the management of renal 
dysfunction  
General principles:  
Glomerular filtration rate in HF patients depends on intrinsic ren  al function and on a balance 
between afferent and efferent glomerular arterial tonicity. This tonicity is partly regulated by a 
stimulation of angiotensin II and could be affected by [CONTACT_18690]. Moreover, renal dysfunction may develop or may deteriorate in some patients after study drug administration. These recommendations have been developed to guide the investigators in managing patients with renal dysfunction after  randomization. 
Two types of response to serum creatinine increase are descr ibed: 
Surveillance situation  
 
the investigator will check for 
potentially reversible causes of renal dysfunction such as:  
• Non-steroidal anti- inflammatory drug intake, antibiotics, or other tr eatments known to 
affect  creatininemia  
• Volume decrease, including that resulting from excessive dosing of diuretics  
• Urinary  infection  
• Urinary tract  obstruction 
• Study medication  
 
Action situation  
If a patient eGFR decreases by ≥ 40% from baseline (or if ser um creatinine concentration rises 
above 3 mg/dL (265 µmol/L), the investigator will check for potentially reversible causes of renal dysfunction (see above).  
If the investigator judges that study medication has to be stopped, he/she will have to contact [CONTACT_146553]/her designee. Thereafter, serum creatinine assessments 
will have to be repeated at least each week until levels return to acceptable value s. If study medication was stopped, every effort will be done to restart it again, according to clinical conditions. 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 71 
Protocol No. CLCZ696BUS01   
  
 
 
 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 72 
Protocol No. CLCZ696BUS01   
  
 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 73 
Protocol No. CLCZ696BUS01   
  
 

 
 [COMPANY_001]  
Amended Protocol Version 02 (Clean)  Confidential  Page 74 
Protocol No. CLCZ696BUS01   
  
 
